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 Lynch Syndrome (LS), one of the most common hereditary cancer syndromes, is 
primarily known for its substantially increased risks for colorectal cancer. The incidence 
of gynecologic cancers (endometrial and ovarian cancers) equals or exceeds the incidence 
of colorectal cancers in female patients with LS. The prevention and treatment methods 
for these cancers can drastically affect fertility and reproduction. Previous studies with 
cancer patients have revealed challenges in acquiring information related to these topics; 
thus far, no research has assessed whether there is an informational gap regarding fertility 
information for women in the LS population. The purpose of this study was to identify 
the amount of information received related to fertility and reproduction, assess patient 
satisfaction, and characterize current practices of this information delivery within our 
target patient population.  
 Data was collected from 154 women with LS. Likert scales were used to quantify 
the amount of information provided about major themes pertaining to fertility in LS: 
effects of cancer treatment, risk-reducing surgeries, fertility preservation and family 
planning. Overall, participants were more satisfied when they received more information 
about certain topics within these themes. There was a distinct lack of individualization in 
patient care, and lack of uniformity regarding the provision of this information among 
healthcare providers. Participant opinions indicate that genetic counselors may be an 
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1.1 Lynch Syndrome 
A hereditary cancer syndrome is characterized by the inheritance of a genetic 
variant that predisposes its carrier to the development of cancers. Distinguishing features 
of hereditary cancer syndromes include an early onset of cancers, the occurrence of 
multiple primaries in a single individual, and several generations of affected individuals 
within a family. These syndromes account for 5-10% of all cancer diagnoses, and 
contribute to significant morbidity and mortality rates in the populations affected (Nagy, 
2004). In order to reduce the clinical consequences, it is important to identify carriers 
through appropriate screening programs and genetic testing (Robson, 2003). 
Confirmation of a positive genetic diagnosis will detect at-risk individuals, justify 
increased surveillance, aid in medical management, and help in the decision-making  
concerning family planning and prophylactic interventions (Giardiello, 2014).  
Lynch Syndrome (LS) is one of the most common hereditary cancer syndromes, 
with an estimated population prevalence of 1 in 400 (Nagy, 2004). It is characterized by a 
predisposition to a spectrum of cancers, but primarily known for its substantially 
increased risks for colorectal and endometrial cancer. The history of this syndrome began 
in the early 1900s when Dr. Aldred Warthin, a renowned pathologist, observed a pattern 
of gastrointestinal and uterine cancers occurring frequently in a large family [“Family 
G”] (Warthin, 1913). The medical records and family pedigrees in his study provided 
some of the first evidence of the heritable nature of cancer susceptibility, a concept that at 
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the time was still under scrutiny. In the 1960s, Dr. Henry T. Lynch encountered two 
families [“Family N” and “Family M”] that featured an extensive, multi-generational 
history of early onset colorectal cancer, among other cancers; this cancer burden was 
similar to the family described by Warthin (Lynch, 1966). After studying the collective 
data from the three families, Lynch proposed that the presence of a syndromic disorder 
was responsible for the cancer manifestation observed (Sehgal, 2014) and coined the 
name ‘Cancer Family Syndrome’ in 1971. Due to the increased risk for colorectal cancer, 
the condition was renamed Hereditary Nonpolyposis Colorectal Cancer (HNPCC) in 
1984, which differentiated it from the other major inherited colorectal cancer syndrome, 
Familial Adenomatous Polyposis. However, HNPCC was deemed a misnomer, as there is 
a wide variety of extracolonic cancers associated with this syndrome, and was 
subsequently renamed Lynch Syndrome (Cohen, 2014). 
LS is an autosomal dominant condition that increases lifetime risks for colonic 
and extracolonic cancers; the proposed risk values depend on the genetic variant inherited 
in a family, and the sex and age of the affected individual (Tiwari, 2016). LS accounts for 
2-4% of all colorectal cancers (CRC) (Barrow, 2013), and affected individuals have as 
high as a 75% lifetime risk of developing CRC. The median age of diagnosis is between 
44-61 years of age, with approximately 50% of all CRC tumors occurring below the age 
of 50. This age of onset is 20-25 years earlier than the onset in sporadic cases of CRC, 
which is typically at age 70 (Cohen, 2014). The progression of these CRC tumors exhibit 
an accelerated carcinogenesis: small adenomas will develop into carcinomas within 2-3 
years in LS patients, versus the 8-10 years in the general population. Other features of 
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CRC in LS include the presence of synchronous and metasynchronous tumors, and an 
increased incidence of tumors in the proximal colon (Lynch, 2009).  
While CRC is a major clinical consequence in LS, affected individuals also have 
substantial risks for extracolonic tumors. Female carriers of LS have a 15-61% risk for 
developing endometrial cancer, which is much higher than the 1.7% risk of the general 
population (Cohen, 2014; ACOG Practice Bulletin, 2014). The large risk range is due to 
the fact that different genes confer differing risk values. Endometrial cancer in LS also 
has an earlier age of onset at approximately 47-62 years, younger than the general 
population’s typical age of onset at 70 (Cohen, 2014). LS accounts for 2% of all new 
ovarian cancer diagnoses (Malander, 2006). The incidence of ovarian cancer in the 
general population is 1.4%, but females with LS are at an increased risk for ovarian 
cancer (approximately 6.7-12%), manifesting between the ages of 41-51 years (Cohen, 
2014). Both male and female carriers have a 0.7-13% risk of developing gastric cancer, 
which follows the trend of early onset. The lifetime risk for cancer of the urinary tract 
(including the bladder, renal pelvis and ureter) ranges from 1.9-11.2%, again depending 
on the genotype (Barrow, 2013). Individuals with LS are also at an elevated risk for 
cancers of the hepatobiliary tract, small bowel, pancreas and CNS tumors. Furthermore, 
there are variants of LS that are associated with specific cancer manifestations. Muir-
Torre syndrome was originally identified as a separate and distinct condition, but genetic 
testing has proven its place on the LS spectrum. Muir-Torre syndrome is characterized by 
a 9% risk for sebaceous neoplasms in addition to the other cancer risks in LS (South, 
2008). The Turcot variant of LS features CNS tumors, particularly glioblastomas, in 
additional to the elevated risk for other LS-associated cancers (Cohen, 2014).  
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LS is caused by a germline mutation in one of the genes involved in the DNA 
mismatch repair (MMR) pathway: MLH1, MSH2, MSH6, PMS2, or EPCAM. The 
function of the MMR proteins is to proofread the DNA for the presence of base-pair 
mismatches or small insertions or deletions introduced by replication error, and repair the 
mistakes. A compromised MMR system will result in the accumulation of somatic 
mutations, eventually leading to carcinogenesis (Cohen, 2014). In particular, defective 
MMR will cause variations within the microsatellites of the DNA. Microsatellites are 
short repetitive sequences within the genome; microsatellite instability (MSI) is a 
hallmark of LS tumors and is frequently used for patient evaluation (Umar, 2004). It is 
estimated that 80-90% of all LS cases are caused by deleterious mutation in MLH1 and 
MSH2, and the remaining 10-20% of cases are due to MSH6 and PMS2 mutations 
(Giardiello, 2014). Approximately 3% of cases are caused by mutations in the EPCAM 
gene. Although EPCAM is not an MMR protein, certain mutations of EPCAM can lead to 
epigenetic silencing of the MSH2, resulting in a LS phenotype (Kempers, 2011).  
Genotype-phenotype correlations have been elucidated in LS. Individuals with 
MLH1 and MSH2 mutations have the highest incidence risks and the widest array of 
possible cancer manifestations. Mutations in MSH2 also has the highest risk for ovarian 
cancer, approximately 8-12% lifetime risk (Chen, 2007; Bonadona, 2011). Carriers of the 
MSH6 mutation have the highest risk for endometrial cancer, at 16-61% lifetime risk 
(ACOG Practice Bulletin, 2014). The cancer risks for the PMS2 mutation carriers fall at 
the lower end of the previously listed ranges, at 15% (Cohen, 2014). Due to the close 
interaction between EPCAM and MSH2, individuals with an EPCAM mutation have 
similar CRC risks as MSH2, but a reduced risk for endometrial cancer (Kempers, 2011). 
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For healthcare providers, it is important to note that LS features differing rates of 
penetrance depending on the genotype, and variable expressivity of cancers between 
family members with the same mutation (Cohen, 2014). 
 Genetic testing for LS is recommended for individuals who meet specific clinical 
and pathological guidelines. The original Amsterdam Criteria stipulated that in order to 
qualify for a clinical diagnosis of LS, an individual would need to have at least three 
family members affected with CRC, two successive generations of affected individuals, 
and at least one diagnosis of CRC before the age of 50 (Vasen, 1991). However, this 
criterion did not account for the extracolonic manifestations of LS and was later revised 
to require a family history of “LS-associated cancers” instead of just CRC (Vasen, 1999). 
The Revised Bethesda Guidelines were developed to identify patients at risk for LS who 
did not meet the Amsterdam Criteria, and included a MSI evaluation and 
immunohistochemical staining (IHC) the individual’s CRC or endometrial tumor. If a 
biopsy was found to have a high load of MSI, it would raise suspicion for the presence of 
a germline MMR mutation. An IHC assay screens for the present or absence of MMR 
proteins in the tumor biopsies, which can indicate the presence of a germline mutation 
(Umar, 2004).  
Identification of individuals at-risk for LS through these screening modalities and 
subsequent cascade testing is extremely important, as screening and preventative 
measures can be taken to improve overall morbidity and mortality. At-risk individuals are 
referred to genetic counseling for education about the medical, psychological, and 
familial implications of the disorder, the commencement of genetic testing, and the 
disclosure of the results (Vig, 2012). Once a diagnosis of LS is confirmed, there are 
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detailed management protocols that can be implemented. The National Comprehensive 
Cancer Network (NCCN) guidelines recommend increased surveillance for CRC through 
annual colonoscopies. The commencement age for the colonoscopy does not differ by the 
culprit gene: MLH1, MSH2, MSH6, PMS2 and EPCAM mutation carriers should begin at 
20-25 years. Colonoscopies should begin 2-5 years prior to the earliest diagnosed CRC in 
the family, and be repeated every 2-3 years. Screening for endometrial and ovarian 
cancer can include annual endometrial sampling, serum CA-125 assays and transvaginal 
ultrasound; however, there is no clear evidence supporting this screening, as the available 
modalities do not have sufficient sensitivity or specificity. A prophylactic total abdominal 
hysterectomy and bilateral salpingo-oophorectomy (TAH-BSO) is recommended as a 
risk-reducing option after the completion of childbearing. There is no evidence 
supporting screening for gastric and small bowel cancers, but select individual or families 
may consider an esophagogastroduodenoscopy every 3-5 years beginning at 30-35 years. 
An annual urinalysis beginning at 30-35 years will screen for cancers of the urinary tract. 
A neurologic examination for CNS tumors can begin at 25-30 years. There are no 
screening recommendations for cancers of the hepatobiliary tract and pancreas. Finally, 
patients of reproductive age should be advised about options for prenatal diagnosis of LS 
and assisted reproductive technologies (ART), as well as the risk for Constitutional 






1.2 Implications of Lynch Syndrome on Fertility 
A diagnosis of LS can have significant implications on an individual’s fertility 
and reproductive options. Individuals with LS are at a substantially increased risk for 
developing early onset colorectal cancers. Treatment for CRC can include chemotherapy, 
radiation therapy and surgical resection of the tumor. Different chemotherapeutic agents 
will have different levels of gonadotoxicity. For example, adjuvant therapy with 
fluorouracil (5-FU) will have little effect on fertility, but treatment with oxaliplatin may 
cause irreversible premature ovarian failure (POF). Radiation therapy is commonly used 
to treat rectal cancers, often given neoadjuvantly. The ovaries are extremely sensitive to 
radiation, and the conventional cumulative dose of radiation will cause POF in most 
women (Zbuk, 2009). Pelvic radiation can have obstetrical and neonatal consequences, 
most notably increased rates of miscarriage, preterm labor, placental abnormalities and 
low birthweight. These adverse outcomes are due to myometrial fibrosis, uterine 
vasculature damage and endometrial injury (Wo, 2009). There may be inherent risks for 
infertility associated with surgery for CRC. Postoperative adhesion formation in the 
pelvis can alter the normal anatomic relationship between the uterine tubes and ovaries, 
resulting in difficulties to conceive (Olsen, 2012).  
A study conducted by Stupart et al. (2015) assessed the fertility rates of 
unaffected MMR mutations carriers and affected carriers with a CRC diagnosis. For the 
purposes of this study, “total fertility rates” was defined as the average number of 
children a hypothetical cohort of affected women would have if they had children at the 
population age-specific rate during their entire life. Total fertility for women with a CRC 
diagnosis decreased by almost 40% in comparison to the unaffected group. While this 
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appears to be a large reduction, the authors noted that the decision to have children is 
influenced by many psychosocial factors. Nevertheless, cancer-related mortality and 
morbidity, and effects of surgery and therapy can all be expected to play a role in the 
decrease of fertility observed in women with CRC. It is also important to note that, while 
fertility concerns may be incorporated as deciding factors, the exact management of CRC 
should be tailored to each patient’s presentation, with the pros and cons of the chosen 
treatments weighed accordingly (Zbuk, 2009).  
The incidence of gynecologic cancers equals or exceeds the incidence of 
colorectal cancers in female patients with LS (Mills, 2014). LS is responsible for a high 
proportion of endometrial cancer cases diagnosed below the age of 45, approximately 9-
12% (Dorais, 2011). In the treatment of gynecologic malignancies in young adults, the 
interventions to spare fertility are concentrated on less radical surgery or a lower dose of 
drug therapy to spare the reproductive organs as much as possible for subsequent fertility 
(Lee, 2006). The standard treatment for endometrial cancer is a total abdominal 
hysterectomy and bilateral salpingo-oophorectomy (TAH-BSO) with a retroperitoneal 
lymphadenectomy (Dorais, 2011). Young women can pursue fertility-sparing options, 
which entail a dilation and curettage of the lesion followed by non-gonadotoxic 
chemotherapy or hormone management. The conservative approach to cancer treatment 
is only available for low-grade tumors that are confined to the endometrium; any patient 
who chooses this option must be informed of the risk of an undiagnosed synchronous or 
metasynchronous endometrial tumor, and the increased risk for relapse (Bovicelli, 2012; 
Hahn 2009). Alternately, immediate hysterectomy with ovarian conservation is another 
option for patients who wish to attempt pregnancy using a gestational carrier. However, 
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the rate of concurrent ovarian cancer in patients with premenopausal women with 
endometrial cancer is approximately 11-29% (Evans-Metcalf, 1998). This is likely 
exacerbated in women with Lynch Syndrome, whose baseline risk of ovarian cancer 
increased above the general population. The type of treatment will depend on the type of 
ovarian cancer, but the main treatment is surgery with debulking, with or without 
chemotherapy. The feasibility of fertility sparing surgery as a treatment for ovarian 
cancer is still hotly debated; this is especially due to the fact that ovarian cancer is the 
most lethal gynecologic malignancy and the majority of women present in advanced 
stages (Ditto, 2014; Raja, 2012).  
 While endometrial surveillance may be effective, the value of surveillance for 
ovarian cancer is still under debate (Helder-Woolderink, 2016). The sensitivity and 
specificity of CA-125 screening is known to be poor, and ultrasound detection has many 
limitations, including the variation in result interpretation (Rauh-Hain, 2011). The most 
effective means of reducing cancer mortality is through risk-reducing surgery (RRS). 
Women with Lynch Syndrome are recommended to consider a total abdominal 
hysterectomy and bilateral salpingo-oophorectomy (TAH-BSO) upon the completion of 
childbirth (NCCN, Version 2.2016; Chapman, 2015). However, the temporal pressure to 
pursue RSS has been shown to be a cause of anxiety in women of reproductive age. A 
study by Donnelly et al. (2013) assessed reproductive decision-making in young women 
who were carriers of a BRCA1/2 mutation; these mutations will predispose individuals to 
increased risk for breast and ovarian cancer. That study found that these perceived 
pressures caused distress in the patients and complicated social relationships. In addition, 
a major disadvantage of a TAH-BSO is the early onset of menopause, which can have an 
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increased risk of cardiovascular disease, loss of bone density, vaginal dryness, mood 
disturbances, and reduced libido (Chapman, 2015). 
The field of fertility preservation is rapidly expanding to include multiple 
experimental and non-experimental options for female patients. Gonadal shielding during 
radiation or ovarian transposition (oophoropexy) away from the radiation field can be 
executed to reduce the amount of radiation damage to the ovaries. This technique, 
however, does not protect the uterus from radiation damage. Embryo and oocyte 
cryopreservation are established fertility preservation methods. These techniques require 
ovarian stimulation and harvesting, which can delay therapy, and involve expensive costs 
based on insurance coverage (Lee, 2006). Ovarian tissue cryopreservation is an 
experimental option that does not require ovarian stimulation, but does involve a 
laparoscopic procedure; it is a potential option for patients who need to urgently undergo 
aggressive therapy (ASRM, 2014). Fertility preservation options each come with risks, 
advantages and disadvantages. Interdisciplinary cooperation between surgeons, 
oncologists, gynecologists, reproductive endocrinologists and other healthcare providers 
is necessary for at-risk patients so that individualized options can be offered in advance 
of or concurrently with surgery or adjunctive treatment (Spanos, 2008). Some individuals 
may be concerned about the familial transmission of LS; due to the genetic nature of the 
condition, patients have a 50% chance of passing on their MMR mutation to their 
offspring. Prenatal diagnosis can be offered to expectant couples to determine the 
mutation status of a pregnancy. Preimplantation genetic diagnosis (PGD), offered in 
conjugation with an in vitro fertilization (IVF) cycle, allows for the identification of 
embryos lacking the familial mutation to be selected for implantation (Simpson, 2016). 
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1.3 Informational Exchange between Healthcare Providers and Patients 
Providing patients and their families with adequate information concerning 
treatment and care is an ongoing challenge in most healthcare organizations. Kullberg et 
al. (2015) sought to evaluate patients’ opinions on information provision in oncology 
wards. This study used patient satisfaction to measure the quality of care as perceived by 
the patients. Researchers concluded that there are deficits in the information exchange 
between hospitalized cancer patients and healthcare staff, and that adequate information 
is a prerequisite for patient participation in their own care. The issue of insufficient 
information exchange can therefore affect many areas of a patient’s care. Finney Rutten 
et al. (2016) found that individuals affected with cancer report challenges acquiring 
information for decision-making throughout their care. This study found that information 
seeking among cancer patients has increased from 66.8% in 2003 to 80.8% in 2013, and 
is likely to continue increasing. Another important finding was that the most frequently 
listed first sources of information were healthcare providers and the Internet. Deficits in 
information exchange may be due to providers not rising to meet the increased 
information needs of their patients. It has been previously observed that communication 
difficulties exist in regards to fertility in cancer. In a recent study, participants reported 
that oncology care and fertility care were provided independently of each other, leading 
to fragmentation in both care and information provision (Goossens, 2015).  
The American Society of Clinical Oncology (ASCO) states that oncologists are 
responsible to inform patients about the possible risks for impaired fertility associated 
with their cancer treatment and refer interested patients to reproductive specialists (Lee, 
2006). However, Partridge et al. (2004) surveyed male and female cancer survivors of 
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reproductive age, and discovered that a least half have no memory of a discussion of 
fertility at the commencement of their treatment. In the participants that did recall an 
infertility discussion, most were dissatisfied with the quality and amount of information 
provided. Another study by Strong et al. (2007) echoes a similar sentiment. This study 
sought to quantify the incidence of fertility counseling in women of reproductive age 
prior to treatment for colorectal cancer. Based on medical records, less than 20% of 
women of reproductive age had documentation of counseling for post-treatment fertility. 
An ASCO special article hypothesized reasons why oncologists may not disclose fertility 
information: physicians are likely to prioritize discussions about immediate 
complications of a cancer diagnosis instead of discussing the potential for infertility (Lee, 
2006). If oncologists are not disclosing this information, it creates a knowledge gap for 
patients. In some centers, a nurse specialist is able to fill this gap. Kelvin et al. (2016) 
compared satisfaction with the amount of fertility-related information received between 
reproductive-aged patients who did and did not receive counseling from a fertility clinical 
nurse specialist. The study found that patients benefited from additional in-depth 
counseling and education about fertility-related information. While the above evidence 
listed is not specific to Lynch Syndrome, it is applicable to the care of patients with LS 
due to their risk for early onset cancers that can influence their fertility. Oncologists and 
other healthcare providers may be providing fertility-based information to LS patients 
affected with cancer, but are likely not even in contact with presymptomatic carriers. 
 Genetic counseling is a recommended platform for the discussion of the cancer 
risk and management options for patients diagnosed with a hereditary cancer syndrome. 
The genetic counselor is equipped to comprehensively review the clinical consequences 
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of Lynch Syndrome with both at-risk patients and newly diagnosed cancer patients. Few 
other healthcare providers are involved with the discussion of risks for presymptomatic 
carriers as well as those affected with an LS cancer. Presymptomatic carriers are a 
population that can take advantage of increased surveillance, RRS and family planning. 
Genetic counselors are also involved with conversations related to reproductive concerns 
for this population, including the risk of transmission to offspring and the option of PGD 
(Biesecker, 2001). Previous research has revealed that cancer genetic counselors consider 
discussions of fertility preservation to be a part of their role (Volk, 2012). Goetsch et al. 
(2016) found that reproductive endocrinologists utilize genetic counselors for the care of 
individuals with an inherited cancer syndrome in regards to fertility preservation and 
PGD. Therefore, genetic counselors have a role in the fertility-related care of individuals 
with an inherited cancer syndrome, and may be the best resource to bridge the knowledge 
gap in regard to fertility for patients with LS. 
 
1.4 Fertility-Related Informational Needs in Hereditary Cancer Syndromes  
Another common hereditary cancer syndrome is the Hereditary Breast and 
Ovarian Cancer Syndrome (HBOC), a condition that is caused by mutations in the 
BRCA1 and BRCA2 genes. Mutation carriers have greater than an 80% lifetime risk for 
breast cancer and 40% risk for ovarian cancer by age 70 (Metcalfe, 2000). There have 
been several studies that have evaluated fertility-related information concerns in the 
BRCA1/2 mutation carrier population. Quinn et al. (2010) assessed the informational 
needs of BRCA mutation carriers regarding issues of infertility and fertility options. 
Participants in this study expressed a strong desire for assistance with decision-making 
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and a need for better presentation of available fertility options. Another study by Kim et 
al. (2015) evaluated patient knowledge of the clinical impact of a BSO and views of 
fertility consultations in this patient population. It was noted that patients would benefit 
from additional emphasis on fertility in all of their appointments with healthcare 
providers, including genetic counseling. Studies in HBOC maybe generalizable to other 
hereditary cancer syndromes, including LS. It may be a trend in hereditary cancer 
syndromes that carriers need more accessible information regarding their fertility. 
However, because there are different cancer risks between individuals with HBOC and 
LS, there are different fertility concerns between these two populations. A practice 
guideline released by the National Society of Genetic Counselors (NSGC) states that the 
genetic counselor should include a provision of extensive client resources, including 
information concerning fertility and reproductive choices, when counseling an individual 
with a BRCA1/2 mutation (Berliner, 2012). There has not been a similar guideline 
released in regards to LS. 
In comparison to the extensive amount of data collected on the informational 
needs of BRCA1/2 carriers, very few studies have investigated the needs of patients with 
LS. It can be expected that a deficit of information also exists in LS, but there is little 
research available on this topic. Using data collected from support groups for LS, a study 
by Corines et al (2016) advocated that increased knowledge empowers patients with LS 
to take a proactive role in their own health management. A previous study by Bannon et 
al. (2014) examined the educational and information needs of individuals with LS, but 
this assessment did not explore the informational needs related to fertility and 
reproduction. Therefore, it is important to establish the exact informational needs of this 
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population in order for adequate information provision. Of note, a study by Burton-Chase 
et al. (2017) found that LS CRC survivors reported lower levels of satisfaction with their 
healthcare providers than sporadic CRC survivors, particularly in regard to 
communication. This noted lack of satisfaction may exist broadly for individuals with LS. 
Current studies regarding fertility and reproduction in patients with LS have only 
examined the attitudes towards reproductive decision-making for childbearing, prenatal 
genetic testing and assisted reproductive technologies (ART). Dewanwala et al. (2011) 
compared patient attitudes towards childbearing and prenatal testing before and after 
genetic testing for LS. This study’s findings suggest that individuals with LS are 
interested in prenatal testing and PGD, and would consider having children earlier to 
allow for earlier RRS. Duffour et al. (2015) reported distress among MMR mutation 
carriers in regards to reproductive-decisions making, and increased interest in ART a year 
after genetic testing. These two studies prove that women with Lynch Syndrome are 
interested in the topics of fertility and reproduction, but they do not identify how and 
when these topics are being presented to patients. Thus far, there have not been any 
studies conducted that assess the need for information pertaining to the fertility 




Chapter 2. Assessment of Patient Satisfaction with the Provision of Fertility 
Information in Women with Lynch Syndrome
 
2.1 Abstract 
 Lynch Syndrome (LS), one of the most common hereditary cancer syndromes, is 
primarily known for its substantially increased risks for colorectal cancer. The incidence 
of gynecologic cancers (endometrial and ovarian cancers) equals or exceeds the incidence 
of colorectal cancers in female patients with LS. The prevention and treatment methods 
for these cancers can drastically affect fertility and reproduction. Previous studies with 
cancer patients have revealed challenges in acquiring information related to these topics; 
thus far, no research has assessed whether there is an informational gap regarding fertility 
information for women in the LS population. The purpose of this study was to identify 
the amount of information received related to fertility and reproduction, assess patient 
satisfaction, and characterize current practices of this information delivery within our 
target patient population.  
 Data was collected from 154 women with LS. Likert scales were used to quantify 
the amount of information provided about major themes pertaining to fertility in LS: 
effects of cancer treatment, risk-reducing surgeries, fertility preservation and family 
planning. Overall, participants were more satisfied when they received more information 
about certain topics within these themes. There was a distinct lack of individualization in 
patient care, and lack of uniformity regarding the provision of this information among 
healthcare providers. Participant opinions indicate that genetic counselors may be an 
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 Lynch Syndrome (LS) is one of the most common hereditary cancer syndromes, 
with an estimated population prevalence of 1 in 400 (Nagy, 2004). LS accounts for 2-4% 
of all colorectal (CRC) cancers (Barrow, 2013) and affected individuals have as high as a 
75% lifetime risk of developing CRC (Cohen, 2014). The median age of diagnosis is 
between 44-61 years of age, with approximately 50% of all CRC tumors occurring below 
the age of 50. Female carriers of LS have a 15-61% risk for developing endometrial 
cancer, which is much higher than the 1.7% risk of the general population (Cohen, 2014; 
ACOG Practice Bulletin, 2014). The incidence of ovarian cancer in the general 
population is 1.4%, but females with LS are at an increased risk for ovarian cancer 
(approximately 6.7-12%). Similar to CRC, both the endometrial and ovarian cancers in 
LS manifest at earlier ages than the general population. Additional cancers associated 
with Lynch Syndrome include the risk for gastric, urinary tract, hepatobiliary, pancreatic 
and CNS. 
The risk values for the colonic and extracolonic cancers depend on the genetic 
variant inherited in a family, and the sex and age of the affected individual (Tiwari, 
2016). LS is caused by a germline mutation in one of the genes involved in the DNA 
mismatch repair (MMR) pathway: MLH1, MSH2, MSH6, PMS2, or EPCAM (Lynch, 
2015). Individuals with MLH1 and MSH2 mutations have the highest incidence risks and 
the widest array of possible cancer manifestations. Mutations in MSH2 also has the 
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highest risk for ovarian cancer, approximately 8-12% lifetime risk (Chen, 2007; 
Bonadona, 2011). Carriers of MSH6 mutations have the highest risk for endometrial 
cancer, at 16-61% lifetime risk (ACOG Practice Bulletin, 2014). The cancer risks for the 
PMS2 mutation carriers fall at the lower end of the previously listed ranges, at 15% 
(Cohen, 2014). Due to the close interaction between EPCAM and MSH2, individuals with 
an EPCAM mutation have similar CRC risks as MSH2, but a reduced risk for endometrial 
cancer (Kempers, 2011). For healthcare providers, it is important to note that LS features 
differing rates of penetrance depending on which gene is mutated, and variable 
expressivity of cancers between family members with the same mutation (Cohen, 2014). 
 A diagnosis of Lynch Syndrome can have significant implications on a woman’s 
fertility and reproductive options, particularly due to the incidence and early onset of 
CRC, endometrial and ovarian cancers. Treatment for CRC can include chemotherapy, 
radiation therapy and surgical resection of the tumor, all of which can disrupt the fertility 
of a patient (Zbuk, 2009; Wo, 2009; Olsen, 2012). There are inherent risks for infertility 
associated with surgery for CRC, as postoperative adhesion formation in the pelvis can 
alter the normal anatomic relationship between the uterine tubes and ovaries, resulting in 
difficulties to conceive (Olsen, 2012). A study conducted by Stupart et al. (2015) 
assessed the fertility rates of unaffected MMR mutations carriers and affected carriers 
with a CRC diagnosis: total fertility for women with a CRC diagnosis decreased by 
almost 40% in comparison to the unaffected group. While there are many factors that 
influence the decision to have children, the effects of surgery and therapy for CRC are 
likely strong modifiers.  
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 The incidence of gynecologic cancers equals or exceeds the incidence of 
colorectal cancers in female patients with LS (Mills, 2014). In the treatment of 
endometrial malignancies in young women, the interventions to spare fertility are 
concentrated on less radical surgery or a lower dose of drug therapy to spare the 
reproductive organs as much as possible for subsequent fertility (Lee, 2006). Fertility 
sparing options may be available for ovarian cancer, but its feasibility is still debated as 
ovarian cancer is the most lethal gynecologic malignancy and the majority of women 
present in advanced stages (Ditto, 2014; Raja, 2012). 
 While endometrial surveillance may be effective, the value of surveillance for 
ovarian cancer is still disputed (Helder-Woolderink, 2016). The most effective means of 
reducing gynecologic cancer mortality is through risk-reducing surgery (RRS), and 
women with LS are recommended to consider a total abdominal hysterectomy with 
bilateral salpingo-oophorectomy (TAH-BSO) upon the completion of childbirth (NCCN, 
Version 2.2016). Choosing a TAH-BSO does come an array of disadvantages, including 
the early onset of menopause (Chapman, 2015). Donnelly et al (2013) studied 
reproductive decision-making in young patients with another hereditary cancer syndrome, 
Hereditary Breast and Ovarian Cancer (HBOC), and found that the temporal pressures to 
pursue RSS cause an increase in distress and social complications for the patient, 
particularly in women who have not yet completed childbearing.  
 The field of fertility preservation can provide options for women in the LS 
population; these options can offered in advance of or concurrently with surgery or 
adjunctive treatment (Spanos, 2008). These options include gonadal shielding during 
radiation, ovarian transposition, embryo cryopreservation, etc. (Lee, 2006; ASRM, 2014). 
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Women with LS also have options for reproductive decision-making. Prenatal diagnosis 
can be offered to expectant couples to determine the mutation status of a pregnancy. 
Preimplantation genetic diagnosis (PGD), offered in conjugation with an in vitro 
fertilization (IVF) cycle, allows for the identification of embryos lacking the familial 
mutation to be selected for implantation (Simpson, 2016). 
Interdisciplinary cooperation between healthcare providers is necessary to offer 
individualized options to at-risk patients, but providing patients with adequate 
information concerning treatment and care is an ongoing challenge. Finney Rutten et al. 
(2016) found that individuals affected with cancer report challenges acquiring 
information for decision-making throughout their care. These communication difficulties 
certainly exist in regard to fertility and cancer. In a recent study, participants reported that 
oncology care and fertility care were provided independently of each other, leading to 
fragmentation in both care and information provision (Goossens, 2015). Kelvin et al. 
(2016) compared satisfaction with the amount of fertility-related information received 
between reproductive-aged patients who did and did not receive additional counseling 
about fertility options. The study found that patients benefited from additional in-depth 
counseling and education about fertility-related information.  
The American Society of Clinical Oncology (ASCO) states that oncologists are 
responsible to inform patients about the possible risks for impaired fertility associated 
with their cancer treatment and refer interested patients to reproductive specialists (Lee, 
2006). However, Partridge et al. (2004) surveyed male and female cancer survivors of 
reproductive age, and discovered that a least half have no memory of a discussion of 
fertility at the commencement of their treatment. In the participants that did recall an 
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infertility discussion, most were dissatisfied with the quality and amount of information 
provided. Another study by Strong et al. (2007) sought to quantify the incidence of 
fertility counseling in women of reproductive age prior to treatment for colorectal cancer. 
Based on medical records, less than 20% of women of reproductive age had 
documentation of counseling for post-treatment fertility. An ASCO special article 
hypothesized reasons why oncologists may not disclose fertility information: physicians 
are likely to prioritize discussions about immediate complications of a cancer diagnosis 
instead of discussing the potential for infertility (Lee, 2006). This hypothesis may be true 
of other providers as well, such as gynecologists, reproductive endocrinologists, etc. If 
healthcare providers are not disclosing this information, it creates an informational 
disparity for patients. 
Genetic counselors may be the best resource to bridge the knowledge gap in 
regard to fertility for patients with LS. While oncologists and other healthcare providers 
may be providing fertility-based information to LS patients affected with cancer, these 
providers are likely not in contact with presymptomatic carriers, another group that 
would benefit greatly by a discussion of the fertility risks in LS. Genetic counseling is a 
recommended platform for the discussion of the cancer risk and management options for 
patients diagnosed with a hereditary cancer syndrome, including presymptomatic carriers 
and diagnosed cancer patients. They are equipped to manage conversations related to 
reproductive concerns for this population, including the risk of transmission to offspring 
and the option of preimplantation genetic diagnosis (PGD) (Biesecker, 2001). Previous 
research has revealed that cancer genetic counselors consider discussions of fertility 
preservation to be a part of their role (Volk, 2012). Goetsch et al. (2016) found that 
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reproductive endocrinologists utilize genetic counselors for the care of individuals with 
an inherited cancer syndrome in regards to fertility preservation and PGD. Increased 
emphasis by genetic counselors on topics related to fertility may benefits patients. 
However, there is a lot unknown about the current practices in fertility information 
provision; characterization of current practices is necessary in order to consider the 
implementation new techniques.  
The available research regarding informational needs about fertility and 
reproduction in LS is limited. However, there have been several studies that have 
evaluated the fertility-related information concerns of individuals in the HBOC 
population. Quinn et al. (2010) found a strong desire for assistance with decision-making 
and a need for better presentation of available fertility options. Another study by Kim et 
al. (2015) evaluated patient knowledge of the clinical impact of a prophylactic BSO and 
views of fertility consultations in the HBOC population. It was noted that patients would 
benefit from additional emphasis on fertility in all of their appointments with healthcare 
providers, including genetic counseling. These studies indicate that, overall, there needs 
to be a more focused provision of fertility information to mutation carriers in HBOC. It 
can be expected this fertility-related information deficit also exists for patients with LS. 
Current studies regarding fertility and reproduction in patients with LS have only 
examined the attitudes towards reproductive decision-making for childbearing, prenatal 
genetic testing and assisted reproductive technologies (Dewanwala, 2011; Duffour, 
2015). The available research indicates that women with LS are interested in the topics of 
fertility and reproduction, but thus far, no research has assessed the information gap 
regarding fertility and reproduction information for this patient population. This study 
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sought to evaluate the current practices of information delivery by identifying the amount 
of information received on specific topics related to fertility and reproduction, assess 
patient satisfaction of the disclosure of this information, and identify ways to establish a 
more comprehensive care regimen for women with LS. 
 
2.3 Materials and Methods 
Study Population  
 This research study collected quantitative and qualitative data from women with 
LS. From this population, both presymptomatic women and women affected with cancer 
were invited to participate. However, individuals were required to meet specific 
eligibility criteria in order to proceed with the questionnaire. The eligibility criteria 
ensured that only the opinions of the targeted patient population would be captured by the 
study. Participants must have been diagnosed with LS at a reproductive age, which for 
the purposes of this study is defined as between the ages of 18-45. Participants were also 
required to have a known pathogenic mutation in an MMR gene; pathogenic mutations 
are clinically actionable, and would therefore warrant the initiation of an appropriate 
management protocol. Additionally, there was specific exclusionary criteria: participants 
with a recent diagnosis who have not returned for a follow-up appointment with their 
healthcare provider were excluded from this study, as their initial appointment may not 
have covered all of the relevant information to pertaining to their diagnosis with LS. 
Males were also excluded from participating in the questionnaire, as the fertility concerns 
for LS differ between men and women.  Eligibility and ineligibility were determined by a 
series of questions at the beginning of the survey; participants who were determined to be 
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ineligible were skipped out of the questionnaire using the branch logic function of the 
survey programming software provided by SurveyMonkey.com.  
Survey Distribution 
 Participants were recruited by an invitational flyer (Appendixes A and B) to take 
the online survey. The principle investigator contacted different online support 
organizations for individuals with cancer via e-mail to request participation. The e-mail 
request explained the purpose of the research study and asked for assistance in 
distributing the invitation and link for the online survey to its members. The invitation 
was distributed through the following organizations: the Hereditary Colon Cancer 
Foundation, I Have Lynch Syndrome, Inc., Lynch Syndrome International, and the 
Oncofertility Consortium. The participating organizations circulated the invitations 
through e-mailing lists, websites, Facebook pages, Twitter, and other mediums of 
communication. The survey link was issued between September and October 2016, and 
was available for completion through December 15, 2016.  
Instrumentation 
 For this research study, an original online survey was developed through 
SurveyMonkey.com. The principle investigator constructed the questionnaire (Appendix 
C), which was comprised of both quantitative and qualitative questions, following a 
mixed methods research model. Quantitative questions were used to measure categorical 
information about the participants, while the qualitative questions were used to provide 
deeper insight into the participants’ experience in regard to fertility and LS. The 
questionnaire consisted of a series of multiple choice, Likert scale, and free response 
questions designed to assess the participant’s overall satisfaction with the fertility-related 
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information given to them by their healthcare provider(s) upon or after their diagnosis of 
LS. Within the questionnaire, definitions were provided for some of the terminology used 
in order to promote participant comprehension. The consent agreement was provided on 
the first page of the questionnaire (Appendix D); in order to move forward in the 
questionnaire, participants needed to indicate their consent.  
 Standard demographic information obtained related to the participant’s current 
age, gender, level of education, relationship status, country and region of residency, and 
ethnicity. The survey also included questions specific to LS in order to further categorize 
the participants: age at diagnosis, relationship status at the time of diagnosis, familial 
MMR gene, and whether or not the participant was affected with cancer at the time of 
their diagnosis. The demographic and categorical data provided variables for correlation 
studies during the statistical analysis. 
 The rest of the questionnaire was divided into four sections, which each focused 
on a different aspect of fertility concerns in LS: effects of cancer treatment, prophylactic 
surgery, fertility preservation, and family planning. All four sections had a similar 
composition of questions. Each section had a Likert scale, which aimed at assessing the 
amount information provided about specific topics related to the section heading. Other 
questions in the sections evaluated additional features of information provision, such as 
the timing of the information provision and the healthcare provider involved. The final 
question in each section assessed the participant’s overall satisfaction with the 
information provided for the topics; this part of the questionnaire format was adapted 
from a previous study by Kelvin et al. (2016). For this question, participants could select 
whether they were “satisfied,” “not satisfied,” or “not interested” in the topics covered by 
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that section. Participants also had the option of providing additional comments at the end 
of every section. The last series of questions in the survey focused on the utility of 
genetic counseling for fertility-related information provision for women with LS.  
Data Analysis 
 Statistical analysis for the quantitative data was conducted using Statistical 
Package for the Social Sciences 24.0 (SPSS). While the four main sections of the 
questionnaire were analyzed independently of each other, the same analyses were 
conducted for each section. The primary assessment focused on how the amount of 
information provided about specific topics modified the satisfaction of the participants; 
this analysis was conducted via one-way ANOVA. The amount of information provided 
was quantified by calculating the average response to each item in the Likert scale 
questions; the response of each item was coded 1 (“I received no information about this 
topic”) through 5 (“I received a lot of information about this topic”).  
 A series of additional one-way ANOVAs were conducted to assess for association 
between the amount of information provided and other modifying variables. The 
variables were dichotomous to allow for comparisons: individuals affected with cancer 
vs. presymptomatic carriers, individuals who had completed childbearing vs. those that 
had not completed childbearing, and a comparison between the gene implicated in the 
family. Chi-Square for association tests were conducted to assess overall satisfaction 
between difference groups of participants. Pearson’s correlation and descriptive statistics 
were used to evaluate the rest of the data, including demographic information, and 
information collected about healthcare providers, and topics discussed by genetic 
counselors.  
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 Responses to the open-ended questions were analyzed through inductive analysis, 
and organized based on common themes. The themes were coded by the principle 
investigator and reviewed by all authors. Participants’ responses to these questions were 
brief and covered a limited range of topics; however, they offered valuable insight into 
the personal experience of the participants. 
 In order to maximize the amount of data collected in this study, partially 
completed surveys were included in the data analysis. Participants needed to have 




 Of the 274 individuals that began the questionnaire, 172 met the eligibility 
criteria. Ineligible participants included men (N=2), minors (N=2), individuals diagnosed 
with LS after the age of 45 (N=62), individuals without a known pathogenic variant in an 
MMR gene (or EPCAM) (N=14), and individuals who did not return to their healthcare 
provider after their diagnosis (N=9). Of the 172 participants who met the eligibility 
criteria, 18 individuals did not complete at least two of the four major sections within the 
questionnaire. This resulted in a total of 154 participants who were both within our target 
population and had completed at least half of the questionnaire. 
Demographics 
 The demographic information for the participants in this study is depicted in 
Table 2.1. The majority of women who participated in this study were between the ages 
of 36-45 (40.2%), Caucasian (95.4%), married (72.0%), college-educated (43.8%), and 
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living in the United States (85.4%). Almost half (46.1%) were diagnosed with LS 
between the ages of 26-35. Participants were asked to report which gene was responsible 
for their LS: MLH1 was reported by 28.6%, MSH2 by 44.8%, MSH6 by 13.6%, PMS2 by 
11.7%, and EPCAM by 1.3%. 
 Most of the participants (61.7%, N=95) were presymptomatic at the time of their 
diagnosis with LS, indicating that they had pursued predictive genetic testing (referred to 
in this study as “presymptomatic carriers”). The remaining 38.3% (N=59) were 
diagnosed with cancer before they were found to have LS (Table 2.2). Participants were 
asked to report which cancer(s) they were diagnosed with: 58.8% reported colorectal 
cancer, 19.1% reported endometrial cancer, 8.8% reported ovarian cancer, and 13.2% 
selected “Other.” Those that selected “Other” reported a variety of cancers, including 
breast, thyroid, and sebaceous carcinoma. Of note, many individuals reported multiple 
cancers at early ages of onset, which is not unexpected within this patient population. 
 Participants were asked to report their status in family planning at the time of their 
diagnosis with LS. Individuals who had completed their family prior to their diagnosis 
accounts for 48.7% (N=75). The remaining 51.3% (N=79) had not yet completed their 
family (Table 2.2). 
Cancer Risks and Effects of Cancer Treatment 
 This section of the questionnaire collected data on the amount of information 
provided to the participants about cancers risks and the effects of cancer treatment on 
fertility. Skip logic was used to identify participants who have spoken with their 
healthcare provider about the potential impacts of cancer treatment on fertility. Only 
34.4% (N=53) of participants completed the corresponding section of the questionnaire.
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 A one-way ANOVA was conducted to determine if the satisfaction status of the 
participants was altered depending on the amount of information provided about a given 
topic relating to cancer risks in LS and the effects of cancer treatment on fertility (Table 
2.3). There was a trend towards statistical significance (p≤.05) for one topic (“The risk 
for cancer will differ based on your gene”) [F(2, 50)=3.010, p=.058]: individuals who 
received more information about this topic reported satisfaction with their experience. 
 A one-way ANOVA was conducted to identify whether or not there is a 
difference in the amount of information provided about the topics in this section to 
individuals that were affected with cancer at the time of their diagnosis with LS and 
presymptomatic carriers with LS (Table 2.4). Statistically significant differences were 
observed for one topic: “The risk for cancer will differ based on your gene” [F(1, 
52)=4.828, p=.032]. Additionally, a trend toward statistical significance was noted for 
“The effects of radiation on your reproductive organs” [F(1, 51)=3.513, p=.067]. For 
these two topics, presymptomatic carriers received more information than individuals 
affected with cancer. 
 A one-way ANOVA was conducted to establish whether there was a difference in 
the amount of information provided between individuals who had completed their family 
and those who had not completed their family at the time of their diagnosis with LS 
(Table 2.5). There were no statistically significant findings observed. 
 A one-way ANOVA was conducted to examine whether or not there was a 
difference in LS. There were no statistically significant findings observed. 
 In order to identify the healthcare providers involved in the provision of this 
information, participants were provided a list of healthcare providers and asked to select 
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the provider(s) who discussed with them information about cancer risk and the effects of 
cancer treatment (Figure 2.1). The majority of participants selected oncologist (33.0%, 
N=29), and the second most frequently selected provider was genetic counselor (24.0%, 
N=21). Only 2.0% of participants (N=5) reported that no healthcare provider discussed 
the information with them. Next, the participants were asked to select the healthcare 
provider was most effective at discussing this information: 43.0% of individuals selected 
oncologist and 26% selected genetic counselor.  
 Pearson’s correlation was run to assess the relationship between the timing of the 
information and participant satisfaction. There was a statistically significant negative 
correlation (r2=-.386, p=.004) between these variables: individuals who received 
information about these topics greater than 6 months after their diagnosis with LS were 
less satisfied. 
 Finally, participants were asked to share any comments they had about this 
section of the survey. Many participants reported that the treatment of their cancer took 
precedence over every other concern (N=8). One participant stated: 
 “I was more overwhelmed with my cancer diagnosis and cancer treatment.  
 (Treatment) was a priority, but more information (about the effects) would have 
 been nice.” 
Others participants revealed that they would have preferred a more focused discussion 
about the effects on cancer treatment on fertility (N=5): 
 “I would have preferred to have had more of a conversation about my options 
 with a specialist in fertility. I also would have liked follow up appointment/s post-
 treatment to assess if my fertility had been effected.” 
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Risk-Reducing Surgery 
 This section of the questionnaire collected data on the amount of information 
provided to the participants about the risk-reducing surgical options for women with LS. 
Skip logic was used to identify participants who have spoken with their healthcare 
provider about risk-reducing surgeries. The majority of participants, 85.7% (N=132), 
completed this part of the questionnaire. More than half (51.5%, N=68) reported that they 
had some type of prophylactic surgery at the time of this questionnaire, and 58.8% 
(N=40) of those participants were presymptomatic carriers. 
 A one-way ANOVA was conducted to determine if the satisfaction status of the 
participants was altered depending on the amount of information provided about a given 
topic relating to risk-reducing surgery options (Table 2.6). Statistically significant 
differences were observed for five of six topics: “The timing of a risk-reducing 
hysterectomy” [F(2, 128)=6.875, p=.001], “The timing of a risk-reducing oophorectomy” 
[F(2,128)=9.617, p=.000], “My family history should be considered when planning for a 
risk-reducing surgery” [F(2,127)=5.247, p=.006], “The side effects of a risk-reducing 
oophorectomy before menopause” [F(2,128), p=.000], and “The option of a risk-reducing 
hysterectomy with ovarian preservation” [F(2,128)=7.160, p=.001]. For these topics, 
individuals who received more information about this topic reported satisfaction with 
their experience. 
 A one-way ANOVA was conducted to identify whether or not there is a 
difference in the amount of information provided about the topics in this section to 
individuals that were affected with cancer at the time of their diagnosis with LS and 
presymptomatic carriers with LS (Table 2.7). Statistically significant differences were 
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observed for two topics: “The option of a risk-reducing hysterectomy with ovarian 
preservation” [F(1, 130)=4.828, p=0.32], and “The use of birth control to reduce my 
cancer risk” [F(1, 130)=4.183, p=.043]. For these two topics, presymptomatic carriers 
received more information than individuals affected with cancer. 
 A one-way ANOVA was conducted to establish whether there was a difference in 
the amount of information provided between individuals who had completed their family 
and those who had not competed their family (Table 2.8). Statistically significant findings 
were observed for two of the six topics: “The side effects of a risk-reducing 
oophorectomy before menopause” [F(1, 130)=5.861, p=.017], and “The use of birth 
control to reduce my cancer risk [F(1, 130)=9.473, p=.003]. For these topics, individuals 
who had completed their families received more information than individuals who had 
not completed their family. 
 A one-way ANOVA was conducted to examine whether or not there was a 
difference in the amount of information provided to the participant based on the gene that 
caused their LS. There were no statistically significant findings observed. 
 Participants were provided a list of healthcare providers and asked to select the 
provider(s) who discussed with them information about risk reducing surgeries (Figure 
2.2). The majority of participants selected gynecologist (35.0%, N=77), and the second 
most frequently selected provider was genetic counselor (33.0%, N=73). Only 1% of 
participants (N=3) reported that no healthcare provider discussed the information with 
them. Next, the participants were asked to select the healthcare provider was most 
effective at discussing this information: 41.0% of individuals selected gynecologist, while 
37% selected genetic counselor. 
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 Pearson’s correlation was run to assess the relationship between the timing of the 
information provision about risk-reducing surgeries and participant satisfaction. There 
were no statistically significant findings. 
 Participants were asked to share any comments they had about this section of the 
survey. One theme that emerged is that, prior to having a risk-reducing surgery, there was 
very little discussion about post-surgery quality of life (N=11). Many individuals 
reported that they felt that the symptoms of surgical menopause had not been adequately 
communicated to them. 
 “I did not feel like I had enough information on menopause (or) hormone 
 replacement options instead (of surgery).” 
Another theme was the pressure to pursue surgery (N=8). One participant shared: 
 “I guess I was made to feel that I didn't have much of a choice if I wanted to avoid 
 cancer. It was presented along the lines that there was no "reason to keep those 
 organs" since I was finished having children. I was made to feel that I was lucky 
 to have not been diagnosed with cancer so far, so (I should) have everything 
 removed immediately.” 
Another participant said: 
 “I did not have cancer but consulted with a gynecologic oncologist. I could tell 
 she was unhappy with my decision to keep one ovary.” 
Fertility Preservation 
 This section of the questionnaire collected data on the amount of information 
provided to the participants about fertility preservation techniques. This section did not 
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use the Skip Logic function used in the previous sections. Almost all of the participants 
(97.4%, N=150) completed this section. 
 A one-way ANOVA was conducted to determine if the satisfaction status of the 
participants was altered depending on the amount of information provided about a given 
topic relating to fertility preservation (Table 2.9). Statistically significant differences 
were observed for all four topics: “The option to shield or move the ovaries during 
radiation therapy” [F(2, 140)=7.200, p=.001], “Embryo or egg cryopreservation 
(freezing)” [F(2,140)=34.887, p=.000], “Ovarian tissue cryopreservation (freezing)” 
[F(2,140)=14.606, p=.000], and “Ovarian stimulation will delay cancer treatment” 
[F(2,140)=13.134, p=.000]. For these topics, individuals who received more information 
about this topic reported satisfaction with their experience. 
 A one-way ANOVA was conducted to identify whether or not there is a 
difference in the amount of information provided about the topics in this section to 
individuals that were affected with cancer at the time of their diagnosis with LS and 
presymptomatic carriers with LS (Table 2.10). There were no statistically significant 
findings observed in this analysis. 
 A one-way ANOVA was conducted to establish whether there was a difference in 
the amount of information provided between individuals who had completed their family 
and those who had not completed their family at the time of their diagnosis with LS 
(Table 2.11). Statistically significant findings were observed for all four topics: “The 
option to shield or move the ovaries during radiation therapy” [F(1, 148)=4.375, p=.038], 
“Embryo or egg cryopreservation (freezing)” [F(1, 148)=18.915, p=.000], “Ovarian 
tissue cryopreservation (freezing)” [F(1, 148)=18.126, p=.000], and “Ovarian stimulation 
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will delay cancer treatment” [F(1, 148)=8.017, p=.005]. For these topics, individuals who 
had not completed their families received more information than those that had 
completed their families. 
 A one-way ANOVA was conducted to examine whether or not there was a 
difference in the amount of information provided to the participant based on the gene that 
caused their LS. There were no statistically significant findings observed. 
 In order to identify the healthcare providers involved in the provision of this 
information, participants were provided a list of healthcare providers and asked to select 
the provider(s) who discussed with them information about fertility preservation (Figure 
2.3). The most frequently selected healthcare provider was gynecologist (13.0%, N=21), 
and the second was oncologist (9.0%, N=14). However, 63.0% of participants (N=102) 
reported that no healthcare provider discussed the information with them. Next, the 
participants were asked to select the healthcare provider was most effective at discussing 
this information: there was no strong consensus, with 31.0% selecting oncologist, and 
27.0% selecting gynecologist.  
 Pearson’s correlation was run to assess the relationship between the timing of the 
information provision about fertility preservation and participant satisfaction. There were 
no statistically significant findings. 
 The final question of this section was an open-ended question, requesting 
participants to share any additional comments. Some participants reported that their 
healthcare providers appeared to make assumptions about their interest in this type of 
information (N=5). As one participant described: 
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 “My doctor was more apt to write off any preservation because I have two 
 children rather than being interested if we wanted anymore.” 
Another subset of participants revealed that, due to the lack of information they received 
from their healthcare providers, they had to research these topics themselves (N=7). One 
participant acknowledged the inequality of the situation, saying: 
 “I was satisfied because I was a self advocate and did my own research. I met 
 another young woman who went through treatment a few months before me at the 
 same place, and she did not receive the information I did (because she didn't 
 initiate conversation). This is a huge problem; young women need to be told their 
 options.” 
Family Planning 
 This section of the questionnaire collected data on the amount of information 
provided to the participants about family planning options. This section did not have a 
Skip Logic function. Again, almost all of the participants (90.3%, N=139) completed this 
section. 
 A one-way ANOVA was conducted to determine if the satisfaction status of the 
participants was altered depending on the amount of information provided about a given 
topic relating to family planning (Table 2.12). Statistically significant differences were 
observed for all six topics: “The chance that your children will have Lynch Syndrome” 
[F(2, 130)=10.619, p=.001], “The use of an in vitro fertilization (IVF) cycle” 
[F(2,130)=15.178, p=.000], “Prenatal diagnosis for Lynch Syndrome” [F(2,129)=10.284, 
p=.000], “Preimplantation genetic diagnosis (PGD) for Lynch Syndrome” 
[F(2,129)=8.471, p=.000], “Adoption” [F(2,129)=9.762, p=.000], and “Surrogacy” 
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[F(2,129)=9.688, p=.000]. For these topics, individuals who received more information 
about this topic reported satisfaction with their experience.  
 A one-way ANOVA was conducted to identify whether or not there is a 
difference in the amount of information provided about the topics in this section to 
individuals that were affected with cancer at the time of their diagnosis with LS and 
presymptomatic carriers with LS (Table 2.13). There was a trend towards statistical 
significance for one topic: “The chance that your children will have Lynch Syndrome” 
[F(1, 137)=3.496, p=.064]. For this topic, presymptomatic carriers received more 
information than individuals affected with cancer. 
 A one-way ANOVA was conducted to establish whether there was a difference in 
the amount of information provided between individuals who had completed their family 
and those who had not completed their family at the time of their diagnosis with LS 
(Table 2.14). Statistically significant findings were observed for all six topics: “The 
chance that your children will have Lynch Syndrome” [F(1, 137)=15.145, p=.000], “The 
use of an in vitro fertilization (IVF) cycle” [F(1, 137)=36.238, p=.000], “Prenatal 
diagnosis for Lynch Syndrome” [F(1, 136)=18.022, p=.000], “Preimplantation genetic 
diagnosis (PGD) for Lynch Syndrome” [F(1, 136)=18.487, p-.000], “Adoption” [F(1, 
136)=21.716, p=.000], and “Surrogacy” [F(1, 136)=19.557, p=.000]. For these topics, 
individuals who had not completed their families received more information than those 
that had completed their families. 
 A one-way ANOVA was conducted to examine whether or not there was a 
difference in the amount of information provided to the participant based on the gene that 
caused their LS. One statistically significant finding was observed: individuals who 
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reported having a mutation in the EPCAM gene received less information about these 
topics than individuals with mutations in MSH1, MLH2, MSH6 and PMS2 [F(4, 
134)=2.77, p=.030]. 
 In order to identify the healthcare providers involved in the provision of this 
information, participants were provided a list of healthcare providers and asked to select 
the provider(s) who discussed with them information about fertility preservation (Figure 
2.4). The most frequently selected healthcare provider was genetic counselor (29.0%, 
N=47), and the second was gynecologist (9.0%, N=32). Approximately one third (32.0%, 
N=51) of participants reported that no healthcare provider discussed the information with 
them. Next, the participants were asked to select the healthcare provider was most 
effective at discussing this information: 51% selected genetic counselor. 
 Pearson’s correlation was run to assess the relationship between the timing of the 
information provision about family planning and participant satisfaction. There were no 
statistically significant findings. 
 Finally, participants were asked to share any additional comments they had about 
this section of the questionnaire. The major theme that emerged from this section is the 
temporal pressure felt by the participants (N=7). One participant shared: 
 “My doctor basically told me if I want anymore children I needed to do it (as 
 soon as possible) then consider hysterectomy. That was all I was told.” 
Overall Satisfaction 
 A chi-square test for association was conducted for overall reported satisfaction 
between individuals who were affected with cancer at the time of their diagnosis and 
presymptomatic carriers. No statistically significant findings were observed. However, 
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there was a trend toward statistical significance for the section about risk-reducing 
surgery options [χ2=4.852, p=.088]: individuals affected with cancer were overall more 
satisfied then presymptomatic carriers with the information they received about these 
topics. 
 A chi-square test for association was conducted for overall reported satisfaction 
between individuals who had completed their families and individuals who had not 
completed their families. There were statistically significant findings for three of the four 
sections: individuals who had completed their family were more satisfied with the 
information they received about cancer risks and the effects of cancer treatment on 
fertility [χ2=15.998, p=.000], fertility preservation [χ2=20.612, p=.000], and family 
planning [χ2=22.615, p=.000]. Additionally, a trend toward statistical significant was 
observed for the other section: individuals who had completed their families were more 
satisfied with the information they received about risk-reducing surgery options 
[χ2=5.570, p=.062]. 
Genetic Counseling 
 The final section of the questionnaire focused on genetic counseling for LS, and 
was completed by 133 individuals. The majority (81.9%, N=109) reported that they had 
met with a certified or licensed genetic counselor. Participants were asked to select which 
topic(s) were introduced to them by their genetic counselor from a list: cancer risk for LS, 
effects of cancer treatment on fertility, risk-reducing surgeries for LS, fertility 
preservation options, and family planning options. The most frequently selected topic 
was cancer risks for LS (reported by 108 participants), followed by risk-reducing 
surgeries for LS (N=89).  
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 Next, participants were asked to select which topics they would have wanted their 
genetic counselor to provide more information about regarding their LS diagnosis. The 
majority of individuals again selected cancer risks for LS and risk-reducing surgeries for 
LS. There was, however, an increase in the amount of participants who selected the other 
options (Figure 2.5).  
Additional Comments 
 At the end of the questionnaire, participants were asked to share their final 
comments about their experience with the topics covered by this research study. From 
these comments, some important themes emerged. The first was the need for more a more 
balanced conversation about the effects of cancer treatment on fertility and the aftermath 
of a risk-reducing surgery (N=6). As one participant illustrated: 
 “Be more honest … It was all sunshine and "you're making the best choice; you 
 want to be around for your family."  I felt very betrayed after surgery when I had 
 to deal with terrible hot flashes, bladder leakage, skin changes.” 
Another theme was the psychological stress that comes with a lack of information about 
their options with LS (N=10): 




 This study explored the informational needs of women with LS. The focus of this 
study was to assess patient satisfaction with the disclosure of information pertaining to 
fertility and reproduction to women with LS, and to measure the amount of information 
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provided about these topics to this patient population. Additionally, this research allows 
us to evaluate the current practices of information delivery by identifying the healthcare 
provider involved in patient education, timing in relation to diagnosis, and the topics of 
this discussion. Analysis of these results can allow us to identify areas for improvement 
in the care and management of women with LS. 
 Overall, participants were more satisfied with their experience when they received 
more information. In the section of the questionnaire about cancer risk and the effects of 
cancer treatment on fertility, we found statistical significance between the amount of 
information provided and satisfaction for only one topic (“The risk for cancer will differ 
based on your gene”). For the remaining four topics, the amount of information provided 
did not affect satisfaction rates. This indicates that “The risk for cancer will differ based 
on your gene” is an important topic to discuss with patients. In the sections about risk-
reducing surgery, fertility preservation and family planning, increased information was 
associated with increased satisfaction for almost all of the covered topics, which suggests 
that this information is important to patients, and therefore should be covered in detail by 
a healthcare provider. Patient satisfaction is an extremely important part of healthcare, 
and satisfaction is a proven measure of healthcare quality and success (Prakash, 2010). 
Additionally, satisfaction has been positively correlated with adherence to screening and 
treatment (Bredart, 2010). These findings prove that tangible changes in the amount of 
information provided to a patient can alter their satisfaction and improve their healthcare 
experience.   
 The Likert scales in this study were utilized to compare the amount of information 
provided to different categories of participants, and assess the relationship between 
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participant satisfaction and information provision. These measures also revealed that, 
overall, participants did not receive a lot of information on these topics. Participants were 
able to select a number 1 through 5 to designate the amount of information they received 
on a specific topic, with 1 equating to “I received no information about this topic” and 5 
equating to “I received a lot of information about this topic.” The calculated average of 
the amount of information provided about the topics was 2.10. It is clear that participants 
did not receive a lot of information about topics relating to fertility and reproduction. 
This may indicate that the average patient is not aware of the plethora of options, 
resources, and support available to them.  
 One initiative of this study was to identify whether there was a difference in the 
amount of information provided to individuals who were affected with cancer at the time 
of their Lynch syndrome diagnosis, and individuals who were presymptomatic at the time 
of their diagnosis. For some topics in the sections about cancer risks and the effects of 
cancer treatment, risk-reducing surgery, and family planning, we observed that 
presymptomatic carriers received more information about certain topics than individuals 
affected with cancer. The differences in information provision between these groups may 
be due to the status of the patient at the time of their diagnosis: individuals with cancer 
may have more pressing matters to discuss than fertility and reproductive information. 
Nonetheless, these differences begs the question of whether or not there should be a 
difference in the amount of information provided between these two subsets of the patient 
population; as there are no available guidelines that direct providers to differentiate the 
information they provided between these two subsets of patients, we should not have 
observed this difference. For example, individuals who are affected with cancer have the 
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same chance of transmitting LS to their current and future children; therefore, this 
information is also essential for their overall care.  
 To further study the differences in the experience of individuals affected with 
cancer and presymptomatic carriers, their overall satisfaction levels were compared 
across the four sections. There was a trend towards statistical significance for the risk-
reducing surgery section. Overall, individuals who were affected with cancer were more 
satisfied than the presymptomatic carriers. This may indicate an increased need for 
healthcare providers to emphasize the risk-reducing surgery options during their 
discussions with that category of patients.  
 Another initiative of this study was to evaluate the differences in the amount of 
information provided to individuals who had completed their families at the time of their 
diagnosis with Lynch syndrome, and those who had not completed their families. While 
there were no differences noted in the section about cancer risk and the effects of cancer 
treatment on fertility, there were statistical findings observed in the other three sections. 
For the risk-reducing surgery section, we found that individuals who had completed their 
families received more information about these topics than the other group. It is not 
unexpected that individuals who have completed their family are receiving more 
information on risk-reducing surgeries, as the NCCN guidelines (NCCN, 2.2016) 
recommends that all women consider a TAH-BSO after completion of childbearing. It 
may be that women who are past childbearing are in a life stage where they are ready for 
such information; however, more research is needed to investigate this difference. In the 
sections about fertility preservation and family planning, individuals who had not 
completed their families received more information about these topics than those that had 
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finished their families. This is a positive finding, as family planning topics are more 
applicable to individuals who have not completed their families. These results show that 
the discussion of family planning seems to be targeted to the appropriate individuals.  
  We compared the overall satisfaction rates over the four sections of this 
questionnaire between individuals who had completed their families and those that had 
not. Overall, individuals who had completed their families were more satisfied with their 
experience than individuals who had not completed their families. Combined with the 
prior results, this indicates that although individuals who have not completed their 
families are receiving more information about these topics, they are not satisfied with 
their experience. This study has identified areas of dissatisfaction, though more research 
is needed to determine why patients are dissatisfied. Possible explanations may be that 
the quality of information is insufficient. Another explanation may be that the 
information is not being individualized to the patient. One participant noted that the 
doctor did not discuss information about fertility preservation because she already had 
children; healthcare providers may be generalizing their discussion and not taking the 
individual concerns of their patients into account.  
 Our participants’ reported gene frequencies did not match up to the expected 
percentages. Many studies quote the percentages listed by Lynch and de la Chappelle 
(2003), who stated that MLH1 and MSH2 account for 90% of reported variants, and 
MSH6 accounts for the majority of the remaining cases. In our study, MLH1 and MSH2 
variants comprised only 73.4% (28.6% and 44.8%, respectively). MSH6 was reported by 
13.6% of participants, PMS2 by 11.7%, and EPCAM by 1.3%. Interestingly, there was 
essentially no statistically significant difference in the amount of information provided to 
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participants based on their reported gene. Our one significant finding, that individuals 
with EPCAM mutation received less information about family planning options, is not 
generalizable, as there were only two participants with EPCAM mutation in our study.  
 There are different cancer risks at different ages depending on the gene that is 
causing LS. For example, individuals with an MSH2 mutation have the highest risk for 
ovarian cancers (Bonadona, 2011); one would assume that these participants should be 
receiving a lot of information on fertility and reproduction. The current NCCN guidelines 
do not differentiate screening or RSS recommendations based on the patient’s genotype; 
our results show that healthcare providers are following those guidelines, as all of our 
participants were receiving similar amounts of information, regardless of genotype. 
However, with clear differences reported on the cancer risks per gene and with this study 
reporting a need for individualization based on the patient, it may be time for professional 
societies to re-evaluate their recommendations for the care and management of 
individuals with LS. Indeed, other studies have echoed our findings. Bonadona et al. 
(2011) noted that while TAH-BSO should be considered for women with MLH1 or 
MSH2, the role of gynecological surgery for MSH6 carriers is debatable. Cohen et al. 
(2014) suggested that it is important to incorporate gene- and age-specific data to provide 
the most comprehensive care of patients with LS. Thus far, gene-specific guidelines have 
not been released from any professional organizations.  
 The timing of information provision can often play a critical role in a patient’s 
healthcare experience. In our study, we found a negative correlation between timing and 
satisfaction for the section about cancer risks and the effects of cancer treatment on 
fertility: individuals who received this information greater than six months after their 
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diagnosis were less satisfied. This is a reasonable finding, as cancer treatment is often 
enacted swiftly, and receiving information about these topics a long period of time after a 
diagnosis could limit the options available to a patient. For the other three sections, there 
were no significant findings about the relationship between timing and information 
provision. This suggests that it may not be necessary to discuss certain topics during the 
initial diagnosis, but that some topics may be presented in the several months following a 
patient’s diagnosis with LS. 
 In this study, we requested that participants report the healthcare provider who 
was involved with the provision of information regarding the topics in the four sections. 
An oncologist, a gynecologist and a genetic counselor were the providers that were most 
often selected, which indicates that these three providers are most often involved in this 
information provision; therefore, those providers should be aware of their responsibility 
in this matter, and ensure that they are discussing this information to their patients, or 
referring the patients to another provider that can manage this role.  
 Notably, in the fertility preservation section, a large percentage (63.0%) of 
participants indicated that no healthcare provider discussed those topics with them. This 
is a major issue, as a lack of discussion about these topics creates an informational gap 
for patients. In regard to fertility preservation, ASCO stated that oncologists are 
responsible to discuss possible risks of impaired fertility and refer interested patients to 
reproductive specialists (Lee, 2006); ACOG does not have specific recommendations 
about these topics in regard to LS (ACOG Practice Bulletin, 2014). Since these two 
providers were most often selected as the source of discussions about fertility 
preservation by our participants, these providers should either be equipped for discussion 
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of these topics, or equipped to make an appropriate referral. Research by Volk et al. 
(2012) revealed that cancer genetic counselors consider discussions of fertility 
preservation to be a part of their role. Therefore, a referral to a genetic counselor may be 
an appropriate avenue to eliminate this informational gap. 
 Additionally, we found that 32.0% of participants reported that no healthcare 
provider discussed with them topics relating to family planning. The current NCCN 
guidelines recommend that patients be informed about inheritance risk, prenatal diagnosis 
and ART options (NCCN, 2.2016). ASCO and ACOG do not have any guidelines 
regarding the discussion of family planning in patients with LS (Lee, 2006; ACOG 
Practice Bulletin, 2014). However, inheritance risk and others topics in this section are 
often featured in genetic counseling sessions for hereditary cancer syndromes. Again, this 
finding provides support to the expanded use of genetic counselors in the care of these 
patients.  
 Participants were also able to select the provider whom they thought was most 
effective at discussing this information. In three of the four sections (cancer risk and 
effects of cancer treatment, risk-reducing surgery options, and family planning), a 
substantial percentage of participants selected genetic counselor. Again, this implies that 
there is a need for expansion of the genetic counselor’s role in regard to the provision of 
this information. As previously stated, genetic counselors may take on the responsibility 
to make sure the above topics are effectively communicated to their patients (Goetsch, 
2016; Volk, 2012; Biesecker, 2011). Increased emphasis by genetic counselors on topics 
related to fertility and reproduction may provide benefit to patients. Additionally, genetic 
counselors are trained in resource awareness, and would be able to bridge an 
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informational gap for a patient by identifying options for a patient to access this 
information.  
 To further study the genetic counseling appointments for our participants, we 
asked which topics pertaining to fertility and reproductive information were discussed by 
their genetic counselor. Individuals could select topics from a list that represented the 
main subjects covered in this questionnaire. The most frequently selected subjects were 
“cancer risk for Lynch syndrome” and “risk-reducing surgeries for Lynch syndrome.” 
However, when asked which topics participants would have wanted their genetic 
counselor to discuss, many individuals selected the other available topics (“effects of 
cancer treatment on fertility”, “fertility preservation options”, and “family planning 
options”) in addition to those two topics. These findings may indicate an increased 
patient interest in an expansion of the topics covered by a genetic counselor in regard to 
fertility and reproductive information, which is a sentiment echoed in the previous 
paragraph.   
 The qualitative aspects of this study allowed for a more in depth understanding of 
the participants’ experience. First, many participants voiced the need for more a focused 
fertility consultation. This may be accomplished through a referral to a fertility specialist, 
or from appropriate delivery of this information from the healthcare provider involved 
with the patient’s care. Additionally, participants felt pressured to pursue risk-reducing 
surgeries, and this pressure appeared be exacerbated by a lack of information about these 
surgeries and the potential side effects. Some participants reported completing their own 
research on these topics because healthcare providers did not readily discuss those topics 
with them. A number of participants who had chosen to pursue a risk-reducing surgery 
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stated that they were not adequately warned about the onset of menopause. And finally, 
lack of information or answers about one’s future with LS can cause significant 
psychological stress, which can negatively impact many aspects of one’s life. Many of 
these reported issues can be ameliorated by increased information provision and targeting 
this provision to the appropriate patients. 
Limitations 
 There are some limitations to consider when evaluating this study. First, there was 
a clear lack of diversity within our study participants. The majority of participants were 
married, educated Caucasians who fit into a narrow sociodemographic band, which 
reduces our ability to generalize this study’s results to all women with LS.  Second, 
participants were asked to recall the content of discussions that had occurred, in some 
cases, many years ago. The responses in retrospective studies such as ours may not be 
entirely accurate due to the chance for inaccurate recall. The topics selected for inclusion 
in this study did not encompass all of the available topics about fertility and reproduction 
in LS; for example, participants were not asked about the information they received about 
the chance for CMMRD in their offspring. Since the NCCN guidelines recommend 
discussion of the chance for CMMRD in patients with LS, future research on this subject 
should include information about that topic. Another limitation is that our participant 
population was acquired through online support groups, which can introduce a sampling 
bias. While this is a limitation, it also adds an interesting layer to our results as 
individuals who participate in support groups are generally “information-seekers”. Our 
study shows that these information-seekers are not getting a lot of information from their 
healthcare providers about fertility and reproductive concerns in LS. Finally, for our 
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ANOVA analyses, we did not meet the assumption of homogeneity of variance, 
indicating that there may be better modes of analyses that could be applied to our dataset. 
Research Recommendations 
 This study has revealed new data about the informational needs regarding fertility 
and reproductive information for women with LS, and provides a number of 
opportunities for future research. Conducting a qualitative study on this subject matter 
would allow for a more in-depth understanding of the participants’ experience, and also 
provide information about the quality of the discussion on these topics, rather than just 
the quantity of information provided. Our study focused on the patient’s perspective of 
their healthcare experience; it would be interesting to conduct this study using 
oncologists, gynecologists and genetic counselors as a participant population. Research 
into how the healthcare providers present this information, the extent of detail they 
include, the types of referrals they make, and the types of patients they target will reveal 
the healthcare providers’ perspective, and may also identify flaws in current practice. 
Finally, the development of specific education tools for the distribution of information 
relating to fertility and reproduction for women with LS may help to eliminate the 
informational gap in knowledge for this patient population. 
 
2.6 Conclusions 
 This study sought to provide insight to the needs of women with LS in respect to 
information about fertility and reproduction. By surveying this patient population, we 
were able to evaluate the current practices of this information delivery and identify areas 
for improvement. Our results establish that this type of information is important to 
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women with LS, and its appropriate provision can contribute to a patient’s overall 
satisfaction with their healthcare experience. However, patients are not receiving a large 
amount of information regarding the topics covered in this study, which can lead to a 
decreased in patient awareness of the options, resources, and support available to them. 
This lack of comprehensive information provision can also increase their perceived 
psychosocial stress.  
 Our results also reveal two seemingly conflicting recommendations: the need for 
uniformity and the need for individualization. It is essential that we create a more 
uniform strategy for the provision of this information to this patient population. 
Guidelines should be created identifying the extent of and type of information that should 
be provided, and the healthcare providers that should be involved with this process. 
However, it is also crucial that this information be individualized to fit the patient’s 
specific needs. In particular, the information provided must to be tailored to the patient’s 
age, current status in regard to cancer burden and family planning, and, most importantly, 
their genotype. 
 Finally, this research implies a need for expansion of the genetic counselor’s role 
in the provision of fertility and reproductive information for women with LS. Participants 
identified genetic counselors as the most effective healthcare provider to discuss these 
topics, and genetic counselors are well equipped to manage the discussion, counseling 
and referral process associated with this subject matter. Increased emphasis by genetic 
counselors on topics related to fertility and reproduction may present a way to eliminate 
the knowledge gap for women with LS. Overall, this study has contributed to our 
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understanding of the perspectives of women with LS, and has provided strategies to 


















































Individual Participant N (%) 
Current Age N=154  
 
Country of Origin1 N=123  
 18-25 years 6 (3.9) 
 
 Australia 6 (4.9) 
 26-35 years 58 (37.7) 
 
 Canada 5 (4.1) 
 36-45 years 62 (40.2) 
 
 New Zealand 1 (0.8) 
 >46 years 28 (18.2) 
 
 Norway 1 (0.8) 
     
 
 Sweden 1 (0.8) 
Age at LS Diagnosis N=154  
 
 United Kingdom 4 (3.2) 
 <18 years 2 (1.3) 
 
 United States 105 (85.4) 
 18-25 years 20 (13.0) 
 
     
 26-35 years 71 (46.1) 
 
Region of the United States N=105  
 36-45 years 61 (39.6) 
 
 Northeast2 27 (25.7) 
     
 
 Southeast3 16 (15.2) 
Gene N=154  
 
 Midwest4 28 (26.7) 
 MLH1 44 (28.6) 
 
 Southwest5 11 (10.5) 
 MSH2 69 (44.8) 
 
 Rocky Mountain6 6 (5.7) 
 MSH6 21 (13.6) 
 
 Pacific7 17 (16.2) 
 PMS2 18 (11.7) 
 
     
 EPCAM 2 (1.3) 
 
Ethnicity N=132  
     
 
 American Indian/Native 3 (2.3) 
Highest Education N=130  
 
 Asian/Pacific Islander 0 (0) 
 Some High School 0 (0) 
 
 Black/African Am. 0 (0) 
 High School/GED 8 (6.2) 
 
 Hispanic or Latino 3 (2.3) 
 Some College 22 (16.9) 
 
 White/Caucasian 126 (95.4) 
 Associate’s Degree 9 (6.9) 
 
    
 Bachelor’s Degree 57 (43.8) 
 
Relationship Status N=154  
 Some Graduate School 7 (5.4) 
 
 Married 111 (72.0) 
 Graduate Degree 27 (20.8) 
 
 Widowed 0 (0) 
    
 
 Divorced 6 (4.0) 
    
 
 Separated 1 (0.6) 
    
 
 In a Domestic Partnership 4 (2.6) 
    
 
 In a Relationship 23 (15.0) 
    
 
 Single, Never Married 9 (5.8) 
1Participants were able to choose from a pre-populated list of 154 countries 
2Includes ME, VT, NH, MA, CT, NY, RI, PA, NJ 
3Includes DE, MD, DC, VA, WV, NC, SC, KY, TN, FL, GA, AL, MS, AR, LA 
4Includes OH, IN, IL, MI, WI, MN, IA, MO, ND, SD, NE, KS 
5Includes OK, TX, NM, AZ 
6Includes CO, UT, WY, MT, ID, NV 
7Includes WA, OR, CA, HI, AK 
 





Which best describes your health status at the time of your diagnosis with LS? N=154  
 I was diagnosed with cancer, then discovered I have LS. 59 (38.3) 
 I had genetic testing and discovered I have LS. 95 (61.7) 
Which best describes your family status at the time of your diagnosis with LS? N=154  
 I had completed my family/ I was not interested in having children. 75 (48.7) 
 I had not completed my family. 79 (51.3) 
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Table 2.3 Amount of Information Provided and Participant Satisfaction: Cancer 
Risks and the Effects of Cancer Treatment 
 
Cancer Risks 
and Effects of 
Cancer 
Treatment 
Not Satisfied Satisfied df F p-
value N Mean SD N Mean SD 
The risk for cancer will 
differ based on your 
gene. 
17 2.53 1.77 29 2.41 1.80 (2, 50) 3.10 0.058 
The risk for cancer will 
differ based on your age. 
17 2.53 1.77 29 3.31 1.87 (2, 49) 0.95 0.393 
The effects of 
chemotherapy on your 
reproductive organs. 
17 2.00 1.80 29 2.76 1.97 (2, 49) 0.85 0.433 
The effects of radiation 
on your reproductive 
organs 
17 1.65 1.90 29 2.03 2.17 (2, 49) 0.29 0.753 
The effects of surgery for 
CRC on your ability to 
conceive a pregnancy. 
17 1.53 1.46 28 2.36 2.04 (2, 49) 1.60 0.212 
 
Table 2.4 Information Provision between Individuals Affected with Cancer vs. 
Presymptomatic Carriers: Cancer Risks and the Effects of Cancer Treatment 
 
Cancer Risks 
and Effects of 
Cancer 
Treatment 
Affected with Cancer Presym. Carrier df F p-
value N Mean SD N Mean SD 
The risk for cancer will 
differ based on your 
gene. 
35 2.54 1.93 19 3.68 1.60 (1, 52) 4.83 0.032 
The risk for cancer will 
differ based on your age. 
34 2.76 1.89 19 3.63 1.74 (1, 51) 2.71 0.106 
The effects of 
chemotherapy on your 
reproductive organs. 
34 2.47 2.08 19 2.42 1.57 (1, 51) 0.01 0.928 
The effects of radiation 
on your reproductive 
organs 
34 1.47 2.11 19 2.53 1.68 (1, 51) 3.51 0.067 
The effects of surgery for 
CRC on your ability to 
conceive a pregnancy. 












Table 2.5 Information Provision between Individuals who have Completed their 
Family vs. Individuals who have not Completed their Family: Cancer Risks and 
Effects of Cancer Treatment 
 
Cancer Risks 
and Effects of 
Cancer 
Treatment 
Completed Family Not Completed Family df F p-
value N Mean SD N Mean SD 
The risk for cancer will 
differ based on your 
gene. 
33 2.64 1.98 21 3.43 1.66 (1, 52) 2.32 0.134 
The risk for cancer will 
differ based on your age. 
32 3.09 1.96 21 3.05 1.77 (1, 51) 0.01 0.931 
The effects of 
chemotherapy on your 
reproductive organs. 
32 2.19 1.84 21 2.86 1.96 (1, 51) 1.60 0.212 
The effects of radiation 
on your reproductive 
organs. 
32 1.53 1.95 21 2.33 2.06 (1, 51) 2.05 0.158 
The effects of surgery for 
CRC on your ability to 
conceive a pregnancy. 
32 1.75 1.81 21 2.24 1.87 (1, 51) 0.89 0.348 
 





Not Satisfied Satisfied df F p-
value N Mean SD N Mean SD 
The timing of a risk-
reducing hysterectomy. 
60 3.42 1.39 67 3.98 1.49 (2, 128) 6.88 0.001 
The timing of a risk-
reducing oophorectomy. 
60 2.80 1.63 67 3.85 1.64 (2, 128) 9.62 0.000 
My family history should 
considered when 
planning for a risk-
reducing surgery. 
59 2.97 1.65 67 3.63 1.75 (2, 127) 5.25 0.006 
The side effects of a risk-
reducing oophorectomy 
before menopause. 
60 2.10 1.31 67 3.64 1.60 (2, 128) 23.03 0.000 




60 1.78 1.30 67 2.79 1.91 (2, 128) 7.16 0.001 
The use of birth control 
to reduce my cancer risk. 











Table 2.7 Information Provision between Individuals Affected with Cancer vs. 




Affected with Cancer Presym. Carrier df F p-
value N Mean SD N Mean SD 
The timing of a risk-
reducing hysterectomy. 
45 3.51 1.80 87 3.74 1.36 (1, 130) 0.64 0.424 
The timing of a risk-
reducing oophorectomy. 
45 3.24 1.94 87 3.33 1.65 (1, 130) 0.08 0.783 
My family history should 
considered when 
planning for a risk-
reducing surgery. 
45 2.98 2.09 86 3.42 1.54 (1, 129) 1.88 0.173 
The side effects of a risk-
reducing oophorectomy 
before menopause. 
45 3.00 1.92 87 2.73 1.57 (1, 130) 0.78 0.378 




45 1.69 1.95 87 2.61 1.53 (1, 130) 8.87 0.003 
The use of birth control 
to reduce my cancer risk. 
45 1.44 1.86 87 2.13 1.79 (1, 130) 4.18 0.043 
 
Table 2.8 Information Provision between Individuals who have Completed their 





Completed Family Not Completed Family df F p-
value N Mean SD N Mean SD 
The timing of a risk-
reducing hysterectomy. 
72 3.79 1.64 60 3.50 1.37 (1, 130) 1.20 0.275 
The timing of a risk-
reducing oophorectomy. 
72 3.62 1.83 60 2.93 1.59 (1, 130) 5.05 0.026 
My family history should 
considered when 
planning for a risk-
reducing surgery. 
72 3.28 1.91 59 3.25 1.56 (1, 129) 0.01 0.939 
The side effects of a risk-
reducing oophorectomy 
before menopause. 
72 3.14 1.72 60 2.43 1.60 (1, 130) 5.86 0.017 




72 2.42 1.90 60 2.15 1.52 (1, 130) 0.77 0.381 
The use of birth control 
to reduce my cancer risk. 
















Not Satisfied Satisfied df F p-
value N Mean SD N Mean SD 
The option to shield or 
move the ovaries during 
radiation therapy. 
65 0.92 1.08 27 1.07 1.75 (2, 140) 7.20 0.001 
Embryo or egg 
cryopreservation. 
65 1.22 1.33 27 2.81 2.09 (2, 140) 34.89 0.000 
Ovarian tissue 
cryopreservation. 
65 0.85 0.67 27 1.41 1.76 (2, 140) 14.60 0.000 
Ovarian stimulation will 
delay cancer treatment. 
65 0.92 0.95 27 1.60 2.10 (2, 140) 13.13 0.000 
 
Table 2.10 Information Provision between Individuals Affected with Cancer vs. 




Affected with Cancer Presym. Carrier df F p-
value N Mean SD N Mean SD 
The option to shield or 
move the ovaries during 
radiation therapy. 
56 0.78 1.53 94 0.66 0.78 (1, 148) 0.44 0.507 
Embryo or egg 
cryopreservation. 
56 1.39 1.99 94 1.06 1.31 (1, 148) 1.49 0.224 
Ovarian tissue 
cryopreservation. 
56 0.70 1.19 94 0.76 0.86 (1, 148) 0.12 0.727 
Ovarian stimulation will 
delay cancer treatment. 
56 0.96 1.61 94 0.69 0.90 (1, 148) 1.77 0.185 
 
Table 2.11 Information Provision between Individuals who have Completed their 




Completed Family Not Completed Family df F p-
value N Mean SD N Mean SD 
The option to shield or 
move the ovaries during 
radiation therapy. 
85 0.54 1.07 65 0.92 1.15 (1, 148) 4.38 0.038 
Embryo or egg 
cryopreservation. 
85 0.72 1.23 65 1.80 1.81 (1, 148) 18.92 0.000 
Ovarian tissue 
cryopreservation. 
85 0.45 0.75 65 1.11 1.15 (1, 148) 18.13 0.000 
Ovarian stimulation will 
delay cancer treatment. 










Table 2.12 Amount of Information Provided and Participant Satisfaction: Family 
Planning 
 
Family Planning Not Satisfied Satisfied df F p-
value N Mean SD N Mean SD 
The chance that your 
children will have Lynch 
syndrome. 
55 3.56 1.61 39 4.41 1.39 (2, 130) 10.62 0.000 
The use of an in vitro 
fertilization (IVF) cycle. 
55 1.71 1.54 39 2.43 2.10 (2, 130) 15.72 0.000 
Prenatal diagnosis for 
Lynch syndrome. 
55 1.69 1.54 38 2.03 1.92 (2, 129) 10.28 0.000 
Preimplantation genetic 
diagnosis (PGD) for 
Lynch syndrome. 
55 1.67 1.56 38 1.87 2.04 (2, 129) 8.47 0.000 
Adoption. 55 1.33 1.35 38 1.37 1.48 (2, 129) 9.76 0.000 
Surrogacy. 55 1.25 1.28 38 1.29 1.56 (2, 129) 9.68 0.000 
 
Table 2.13 Information Provision between Individuals Affected with Cancer vs. 
Presymptomatic Carriers: Family Planning 
 
Family Planning Affected with Cancer Presym. Carrier df F p-
value N Mean SD N Mean SD 
The chance that your 
children will have Lynch 
syndrome. 
53 3.11 2.07 86 3.72 1.72 (1, 137) 3.49 0.064 
The use of an in vitro 
fertilization (IVF) cycle. 
53 1.47 1.97 86 1.52 1.61 (1, 137) 0.03 0.866 
Prenatal diagnosis for 
Lynch syndrome. 
52 1.27 1.73 86 1.49 1.55 (1, 136) 0.59 0.442 
Preimplantation genetic 
diagnosis (PGD) for 
Lynch syndrome. 
52 1.21 1.68 86 1.43 1.65 (1, 136) 0.56 0.455 
Adoption. 52 0.90 1.43 86 1.09 1.20 (1, 136) 0.69 0.407 
Surrogacy. 52 1.06 1.65 86 0.89 0.97 (1, 136) 0.53 0.468 
 
Table 2.14 Information Provision between Individuals who have Completed their 
Family vs. Individuals who have not Completed their Family: Family Planning 
 
Family Planning Completed Family Not Completed Family df F p-
value N Mean SD N Mean SD 
The chance that your 
children will have Lynch 
syndrome. 
79 2.97 2.07 60 4.17 1.33 (1, 137) 15.14 0.000 
The use of an in vitro 
fertilization (IVF) cycle. 
79 0.81 1.33 60 2.42 1.82 (1, 137) 38.24 0.000 
Prenatal diagnosis for 
Lynch syndrome. 
78 0.92 1.44 60 2.03 1.63 (1, 136) 18.02 0.000 
Preimplantation genetic 
diagnosis (PGD) for 
Lynch syndrome. 
78 0.85 1.39 60 2.00 1.76 (1, 136) 18.49 0.000 
Adoption. 78 0.60 0.98 60 1.57 1.44 (1, 136) 21.72 0.000 




Cancer Risks and Effects of Cancer Treatment1 
Which healthcare provider discussed the effects of cancer 
treatment on fertility with you? (Check all that apply) 
Which healthcare provider was most effective at discussing this 
information with you? 
  
1The following abbreviations were used for this chart: Onc. (Oncologist), Gyn. (Gynecologist), RE (Reproductive Endocrinolgist), and 
GC (Genetic Counselor). Additionally, the selection of “No One” indicates that no healthcare provider discussed these topics with the 
participant. 
Figure 2.1 Healthcare Providers: Cancer Risks and Effects of Cancer Treatment 
 
Risk-Reducing Surgery1 
Which healthcare provider discussed risk-reducing surgery 
options with you? (Check all that apply) 
Which healthcare provider was most effective at discussing this 
information with you? 
  
1The following abbreviations were used for this chart: Onc. (Oncologist), Gyn. (Gynecologist), RE (Reproductive Endocrinologist), 
and GC (Genetic Counselor). Additionally, the selection of “No One” indicates that no healthcare provider discussed these topics with 
the participant. 
Figure 2.2 Healthcare Providers: Risk-Reducing Surgery 
 
Fertility Preservation1 
Which healthcare provider discussed fertility preservation 
options with you? (Check all that apply) 
Which healthcare provider was most effective at discussing this 
information with you? 
  
1The following abbreviations were used for this chart: Onc. (Oncologist), Gyn. (Gynecologist), RE (Reproductive Endocrinologist), 
and GC (Genetic Counselor). Additionally, the selection of “No One” indicates that no healthcare provider discussed these topics with 
the participant. 










































































































Which healthcare provider discussed family planning options 
with you (Check all that apply) 
Which healthcare provider was most effective at discussing this 
information with you? 
  
1The following abbreviations were used for this chart: Onc. (Oncologist), Gyn. (Gynecologist), RE (Reproductive Endocrinologist), 
and GC (Genetic Counselor). Additionally, the selection of “No One” indicates that no healthcare provider discussed these topics with 
the participant. 
Figure 2.4 Healthcare Providers: Family Planning 
 
Which topics were introduced to you by your genetic counselor about your Lynch 
Syndrome diagnosis? (Check all that apply) 
 
 
Which topics would you want your genetic counselor to give you more 
information about your Lynch Syndrome diagnosis? (Check all that apply) 
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 This study sought to provide insight to the needs of women with LS in respect to 
information about fertility and reproduction. By surveying this patient population, we 
were able to evaluate the current practices of this information delivery and identify areas 
for improvement. Our results establish that this type of information is important to 
women with LS, and its appropriate provision can contribute to a patient’s overall 
satisfaction with their healthcare experience. However, patients are not receiving a large 
amount of information regarding the topics covered in this study, which can lead to a 
decreased in patient awareness of the options, resources, and support available to them. 
This lack of comprehensive information provision can also increase their perceived 
psychosocial stress.  
 Our results also reveal two seemingly conflicting recommendations: the need for 
uniformity and the need for individualization. It is essential that we create a more 
uniform strategy for the provision of this information to this patient population. 
Guidelines should be created identifying the extent of and type of information that should 
be provided, and the healthcare providers that should be involved with this process. 
However, it is also crucial that this information be individualized to fit the patient’s 
specific needs. In particular, the information provided must to be tailored to the patient’s 
age, current status in regard to cancer burden and family planning, and, most importantly, 
their genotype. 
 62
 Finally, this research implies a need for expansion of the genetic counselor’s role 
in the provision of fertility and reproductive information for women with LS. Participants 
identified genetic counselors as the most effective healthcare provider to discuss these 
topics, and genetic counselors are well equipped to manage the discussion, counseling 
and referral process associated with this subject matter. Increased emphasis by genetic 
counselors on topics related to fertility and reproduction may present a way to eliminate 
the knowledge gap for women with LS. Overall, this study has contributed to our 
understanding of the perspectives of women with LS, and has provided strategies to 
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Lynch Syndrome is an inherited condition that is characterized by an increased 
risk for early onset cancers, including colorectal, endometrial, ovarian and gastric 
















2.) What is your current age? 
 Below 18 years old 
 18-25 years old 
 26-35 years old 
 36-45 years old 
 46 years or older 
 
3.) How old were you when you were diagnosed with Lynch Syndrome? 
 Below 18 years old 
 18-25 years old 
 26-35 years old 
 36-45 years old 












 I do not recall 
 I have a variant of unknown significance 
 
5.) Did you return to a healthcare provider for a follow-up appointment after your 




6.) Select the situation that best applies to you. 
 I was diagnosed with cancer, and afterwards I was found to have Lynch 
Syndrome 
 I pursued genetic testing and found that I have Lynch Syndrome 
 Other (please specify) 
 
7.) What cancer were you diagnosed with? (Check all that apply) 
 Colon cancer 
 Rectal cancer 
 Endometrial cancer 
 Ovarian cancer 
 Gastric cancer 
 Urinary Tract cancer 
 Other cancer (please specify) 
 









 In a domestic partnership or civil union 
 In a relationship 
 Single, never married 
 Other (please specify) 
 
10.) Which of the following best describes your relationship status at the time of your 






 In a domestic partnership or civil union 
 In a relationship 
 Single, never married 
 Other (please specify) 
 
11.) Which of the following best describes your status at the time of your diagnosis with 
Lynch Syndrome? 
 I was done with childbearing because I had completed my family 
 I had not yet completed my family 
 I had not yet started a family but planned to have children in the future 
 I was not interested in having children 
 Other (please specify) 
 
Cancer and Cancer Treatment 
 
12.) Did your provider discuss with you the impact of potential cancer treatment (such as 






13.) Which topics were discussed with you about the effects of cancer treatment on 
fertility? (1- I received no information on this topic, 5- I received a lot of information on 
this topic) 
 
 1 2 3 4 5  Not 
Applicable 
The risk of 
cancer will 
differ based 
on your gene. 
      
The risk of 
cancer will 
differ based 
on your age. 
      





      
The effects of 
radiation on 
your 








your ability to 
conceive a 
pregnancy. 
      
 
14.) Approximately how long after your diagnosis with Lynch Syndrome did you receive 
information about the effects of cancer treatment on fertility? 
 I received this information when I received my diagnosis 
 I received this information within a month after my diagnosis 
 One month after my diagnosis 
 Six months after my diagnosis 
 One year after my diagnosis 
 More than one year after my diagnosis 
 I did not receive this information 
 I do not recall 








 Reproductive Endocrinologist 
 Nurse/Nurse Specialist 
 Genetic Counselor 
 No healthcare provider discussed this information with me 
 Other (please specify) 
 
16.) Which healthcare provider was most effective at discussing this information with 
you? 
 A drop down menu of the above options 
 
17.) What informational resources were provided to you on these topics? 
 A referral to a fertility specialist or reproductive endocrinologist 
 An informational pamphlet or fact sheet 
 A website 
 A book 
 A support group 
 I was not provided any resources about this topic 
 Other (please specify) 
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18.) Which resource was most helpful? 
 A drop box menu of the above options 
 
19.) Were you satisfied with the amount of information you received about the effects of 
cancer treatment on your fertility? 
 I was satisfied with the amount of information I received 
 I was not satisfied because I did not receive enough information 
 I was not satisfied because I did not receive any information 
 I was not interested in receiving this type of information 
 
20.) Please share any additional comments you have. 
  
 
Risk-Reducing Surgery and Other Alternatives 
 
21.) Did your provider discuss with you the impact of risk-reducing surgeries (such as a 






The following definitions will be helpful for the next section of this questionnaire: 
Risk-Reducing Surgery 
 Surgery to reduce the risk of having cancer (also known as prophylactic surgery). 
Hysterectomy 
 Surgery to remove the uterus 
Oophorectomy 
 Surgery to remove one or both of the ovaries 
Hysterectomy with Ovarian Preservation 




22.) Have you had any of the following surgeries because of your diagnosis with Lynch 
Syndrome? (Check all that apply) 
 Risk-Reducing Hysterectomy 
 Risk-Reducing Oophorectomy 
 No, I have not had a risk-reducing surgery 





23.) Which topics were discussed with you about risk-reducing surgery for Lynch 
Syndrome? (1- I received no information on this topic, 5- I received a lot of information 
on this topic) 
 
 
24.) Approximately how long after your diagnosis with Lynch Syndrome did you receive 
information about risk-reducing options? 
 I received this information when I received my diagnosis 
 I received this information within a month after my diagnosis 
 One month after my diagnosis 
 Six months after my diagnosis 
 One year after my diagnosis 
 More than one year after my diagnosis 
 I did not receive this information 
 I do not recall 








 Reproductive Endocrinologist 
 Nurse/Nurse Specialist 
 Genetic Counselor 
 No healthcare provider discussed this information with me 
 Other (please specify) 
 
26.) Which healthcare provider was most effective at discussing this information with 
you? 
 A drop down box of the above options 
 
27.) What informational resources were provided to you on these topics? 
 A referral to a fertility specialist or reproductive endocrinologist 
 An informational pamphlet or fact sheet 
 A website 
 A book 
 A support group 
 I was not provided any resources about this topic 
 Other (please specify) 
 
28.) Which resource was most helpful? 
 A drop down box of the above options 
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29.) Were you satisfied with the amount of information you received about risk-reducing 
options for Lynch Syndrome? 
 I was satisfied with the amount of information I received 
 I was not satisfied because I did not receive enough information 
 I was not satisfied because I did not receive any information 
 I was not interested in receiving this type of information 
 





The following definitions will be helpful for the next section of this questionnaire: 
 
Risk-Reducing Surgery 
     Surgery to reduce the risk of having cancer (also known as prophylactic surgery). 
 
Hysterectomy 
    Surgery to remove the uterus. 
 
Oophorectomy 
    Surgery to remove one or both of the ovaries. 
 
Hysterectomy with Ovarian Preservation 
    Surgery to remove the uterus but keep, or preserve, one or both of the ovaries. 
 
31.) Which topics were discussed with you about fertility preservation options? (1- I 
received no information on this topic, 5- I received a lot of information on this topic) 
 1 2 3 4 5  Not 
Applicable 
The option 
to shield or 
move the ovaries 
during radiation 
therapy. 
      
Embryo or egg 
cryopreservation 
(freezing). 
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32.) Approximately how long after your diagnosis with Lynch Syndrome did you receive 
information about fertility preservation? 
 I received this information when I received my diagnosis 
 I received this information within a month after my diagnosis 
 One month after my diagnosis 
 Six months after my diagnosis 
 One year after my diagnosis 
 More than one year after my diagnosis 
 I did not receive this information 
 I do not recall 








 Reproductive Endocrinologist 
 Nurse/Nurse Specialist 
 Genetic Counselor 
 No healthcare provider discussed this information with me 
 Other (please specify) 
 
34.) Which healthcare provider was most effective at discussing this information with 
you? 
 A drop down box of the above options 
 
35.) What informational resources were provided to you on these topics? 
 A referral to a fertility specialist or reproductive endocrinologist 
 An informational pamphlet or fact sheet 
 A website 
 A book 
 A support group 
 I was not provided any resources about this topic 
 Other (please specify) 
 
36.) Which resource was most helpful? 
 A drop down menu of the above options 
 
37.) Were you satisfied with the amount of information you received about fertility 
preservation? 
 I was satisfied with the amount of information I received 
 I was not satisfied because I did not receive enough information 
 I was not satisfied because I did not receive any information 
 I was not interested in receiving this type of information 
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39.) Which topics were discussed with you about family planning options? (1- I received 
no information on this topic, 5- I received a lot of information on this topic) 
 1 2 3. 4 5  Not 
Applicable 





      
















      
Adoption.       
Surrogacy       
 
40.) Approximately how long after your diagnosis with Lynch Syndrome did you receive 
information about family planning options? 
 I received this information when I received my diagnosis 
 I received this information within a month after my diagnosis 
 One month after my diagnosis 
 Six months after my diagnosis 
 One year after my diagnosis 
 More than one year after my diagnosis 
 I did not receive this information 
 I do not recall 





41.) Which healthcare provider discussed this information with you? 
 Oncologist 
 Gynecologist 
 Reproductive Endocrinologist 
 Nurse/Nurse Specialist 
 Genetic Counselor 
 No healthcare provider discussed this information with me 
 Other (please specify) 
 
42.) Which healthcare provider was most effective at discussing this information with 
you? 
 A drop down menu of the above options 
 
43.) What informational resources were provided to you on these topics? 
 A referral to a fertility specialist or reproductive endocrinologist 
 An informational pamphlet or fact sheet 
 A website 
 A book 
 A support group 
 I was not provided any resources about this topic 
 Other (please specify) 
 
44.) Which resource was most helpful? 
 A drop down menu of the above options 
  
45.) Were you satisfied with the amount of information you received about family 
planning options? 
 I was satisfied with the amount of information I received 
 I was not satisfied because I did not receive enough information 
 I was not satisfied because I did not receive any information 
 I was not interested in receiving this type of information 
 
46.) Please share any additional comments you have. 
  
 
Genetic Counseling for Lynch Syndrome 
 




 Not Sure 
48.) Which topics were introduced to you by your genetic counselor about your 
Lynch Syndrome diagnosis? (Check all that apply) 
 Cancer Risks for Lynch Syndrome 
 The Effects of Cancer Treatment on Fertility 
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 Risk-Reducing Surgeries for Lynch Syndrome 
 Fertility Preservation Options 
 Family Planning Options 
 
49.) Which topics would you want your genetic counselor to give you more 
information about your Lynch Syndrome diagnosis? (Check all that apply) 
 Cancer Risks for Lynch Syndrome 
 The Effects of Cancer Treatment on Fertility 
 Risk-Reducing Surgeries for Lynch Syndrome 
 Fertility Preservation Options 
 Family Planning Options 
 
50.) Please share any additional comments you have. 
  
 
Additional Demographic Information 
 
51.) What is the highest level of education that you have completed? 
 Some High School 
 High School or GED 
 Some College 
 Associate’s Degree 
 Bachelor’s Degree 
 Some Graduate School 
 Graduate School (Master’s, PhD, MD, JD, etc.) 
52.) In what country do you currently reside in? 
 A drop down menu of countries is provided for this question. 
 
53.) What is your ethnicity? 
 American Indian or Alaskan Native 
 Asian or Pacific Islander 
 Black or African American 
 Hispanic or Latino 
 White/Caucasian 
 Prefer not to answer 
 Other (please specify) 
 
54.) Which U.S. region do you currently reside in? 
 Northeast (ME, VT, NH, MA, CT, NY, RI, PA, NJ)  
 Southeast (DE, MD, DC, VA, WV, NC, SC, KY, TN, FL, GA, AL, MS, AR, 
LA) 
 Midwest (OH, IN, IL, MI, WI, MN, IA, MO, ND, SD, NE, KS)  
 Southwest (OK, TX, NM, AZ) 
 Rocky Mountain (CO, UT, WY, MT, ID, NV)  




All participants are invited to enter a drawing for a $25 Visa gift card. If you are 
interested, please select "Yes." You will be guided to a page that requests your name and 
email contact. Your contact information will not be used for any other purposes beyond 
sending you the gift card if you have won. 
 
55.) Are you interested in entering a drawing to win a $25 Visa gift card? 
 Yes  
 No 
 











Appendix D. Participant Consent Agreement
 
We would like to invite women with Lynch Syndrome to participate in a study about the 
delivery of fertility information. The purpose of this study is to understand how 
information about fertility issues is presented to women with Lynch Syndrome. We will 
ask you about your satisfaction of your experience with this topic. 
  
Your participation would be greatly appreciated, as your opinions will increase our 
understanding of the specific needs of women with Lynch Syndrome We believe that the 
results of this study will contribute to better presentation of fertility information to 
patients, the creation of more thorough practice guidelines, and increased consistency in 
the care of this patient population.  
  
Your participation in the study is voluntary, and you can withdraw from the study at any 
time. Participating in the study involves the completion an online survey. The survey is 
anonymous, meaning that we will not collect any personal information that could identify 
you or connect you to your responses. However, if you are interested in being entered 
into a raffle for a $25 Visa gift card, you can include your name and contact information 
at the end of the survey. Your contact information will not be used for any other purposes 
beyond sending you the raffle prize if you have won. This survey should take 
approximately 15 minutes to complete. Questions in the survey will ask you about your 
satisfaction of the delivery and presentation of fertility-related information, the healthcare 
providers involved, the resources that you received, and demographic information about 
yourself.  
  
This study is being conducted by Rachel Hickey, a genetic counseling student at the 
University of South Carolina Medical School for a Master’s Thesis project. Emily 
Jordon, a genetic counselor at the University of South Carolina, is the faculty thesis 
advisor for this study. If you have any questions about this study, please contact us. 
  
Rachel Hickey, B.S. Emily Jordon, M.S., C.G.C. 
University of South Carolina 
2 Medical Park, Suite 103 
Columbia, SC 29203 
 
University of South Carolina 
2 Medical Park, Suite 103 
Columbia, SC 29203 
Rachel.hickey@uscmed.sc.edu Emily.jordon@uscmed.sc.edu 
  
For questions about your rights as a participant, you may contact the Office of Research 
Compliance at the University of South Carolina at (803) 777-7095. 
  




Thank you for sharing your insight. 
 
